



Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review

Tamara Ius¹ · Giovanni Sabatino^{2,32} · Pier Paolo Panciani³ · Marco Maria Fontanella³ · Roberta Rudà^{4,5} · Antonella Castellano⁶ · Giuseppe Maria Vincenzo Barbagallo^{7,8} · Francesco Belotti³ · Riccardo Boccaletti⁹ · Giuseppe Catapano¹⁰ · Gabriele Costantino¹¹ · Alessandro Della Puppa¹² · Francesco Di Meco^{13,14,15} · Filippo Gagliardi¹⁶ · Diego Garbossa¹⁷ · Antonino Francesco Germanò¹⁸ · Maurizio Iacoangeli¹⁹ · Pietro Mortini¹⁶ · Alessandro Olivi² · Federico Pessina^{20,21} · Fabrizio Pignotti^{2,32} · Giampietro Pinna²² · Antonino Raco²³ · Francesco Sala²⁴ · Francesco Signorelli²⁵ · Silvio Sarubbo²⁶ · Miran Skrap¹ · Giannantonio Spena²⁷ · Teresa Somma²⁸ · Carmelo Sturiale²⁹ · Filippo Flavio Angileri¹⁸ · Vincenzo Esposito^{30,31}

Received: 10 January 2023 / Accepted: 20 February 2023
© The Author(s) 2023

Abstract

Purpose The extent of resection (EOR) is an independent prognostic factor for overall survival (OS) in adult patients with Glioma Grade 4 (GG4). The aim of the neuro-oncology section of the Italian Society of Neurosurgery (SINch®) was to provide a general overview of the current trends and technical tools to reach this goal.

Methods A systematic review was performed. The results were divided and ordered, by an expert team of surgeons, to assess the Class of Evidence (CE) and Strength of Recommendation (SR) of perioperative drugs management, imaging, surgery, intraoperative imaging, estimation of EOR, surgery at tumor progression and surgery in elderly patients.

Results A total of 352 studies were identified, including 299 retrospective studies and 53 reviews/meta-analysis. The use of Dexamethasone and the avoidance of prophylaxis with anti-seizure medications reached a CE I and SR A. A preoperative imaging standard protocol was defined with CE II and SR B and usefulness of an early postoperative MRI, with CE II and SR B. The EOR was defined the strongest independent risk factor for both OS and tumor recurrence with CE II and SR B. For intraoperative imaging only the use of 5-ALA reached a CE II and SR B. The estimation of EOR was established to be fundamental in planning postoperative adjuvant treatments with CE II and SR B and the stereotactic image-guided brain biopsy to be the procedure of choice when an extensive surgical resection is not feasible (CE II and SR B).

Conclusions A growing number of evidences evidence support the role of maximal safe resection as primary OS predictor in GG4 patients. The ongoing development of intraoperative techniques for a precise real-time identification of peritumoral functional pathways enables surgeons to maximize EOR minimizing the post-operative morbidity.

Keywords Glioma · Extent of resection · Intraoperative neurophysiological monitoring · Surgical planning · Navigated transcranial magnetic stimulation (nTMS) · Intraoperative imaging

Introduction

The annual incidence of gliomas is approximately of six cases per 100,000 people [1], with a slight prevalence in men. While the majority of cases are sporadic, it is estimated

that about 5% of gliomas show a hereditary component in rare tumor predisposition syndromes (Cowden's Syndrome, Turcot's Syndrome, Lynch's Syndrome, Li Fraumeni's Syndrome and Neurofibromatosis type I and II) [2–5]. Characteristics of clinical onset are widely variable, including new-onset epilepsy, focal deficits, neurocognitive impairment, and symptoms and signs of increased intracranial pressure. Incidental diagnosis is extremely rare [6].

Advances in molecular testing and genomic analysis implies a continuous identification of subgroups with

✉ Pier Paolo Panciani
pierpaolo.panciani@unibs.it

Extended author information available on the last page of the article

different prognosis. As a result of these advances, the 2021 WHO Classification gathers as adult Glioma Grade 4 (GG4) both the Astrocytomas IDH-mutant Grade 4 and the astrocytoma IDH wild-type, which in turn currently defines the Glioblastoma (GBM) class [7].

Recent integrative studies showed that patients diagnosed with these tumors have variable prognosis influenced not only by the molecular profile but also by the resection degree achieved [8–11].

In this clinical setting, different prognostic factors have been suggested, including age, extent of resection (EOR), size of necrosis, and specific molecular markers [i.e., MGMT methylation (O6 -methylguanine-DNA methyltransferase)], mutation of IDH1, IDH2 (isocitrate dehydrogenase) or TERT (telomerase reverse transcriptase), 1p19q codeletion, overexpression of EGFR (epidermal growth factor receptor), PDGFRA (Platelet-derived growth factor receptor alpha) [12, 13].

Compelling evidence, based on objective tumoral volume analysis, supports the role of EOR in GG4 patients as one of the main predictive survival factors [14–18]. Surgical treatment, however, can rarely be considered as radical, due to infiltrating nature, multifocal presentation, and ill-defined

tumor margins [9]. Despite years of molecular discoveries and technological advances surgery, followed by radiotherapy (RT) and concomitant and adjuvant chemotherapy (CT) with temozolomide (TMZ) (Stupp protocol), still represents the current standard of care [11, 19].

Contemporary technological and conceptual innovations have thus improved the safety of surgical resection, while expanding the surgical options and indications for GG4 surgical treatment [20, 21]. Several techniques currently used during surgery, such as intraoperative ultrasound (iUS), cortical mapping, sodium fluorescein [22] and 5-ALA fluorescence (5-aminolevulinic acid), tend to favor higher rates of total resection, with apparent increased survival [17, 18, 23].

Unfortunately, the infiltrative growing, the rapid proliferative rate of malignant cells, and the appearance of treatment-resistant cell clones shortly after initial therapy, tend to promote tumor relapse, within 2 cm of resection margins, regardless the EOR [24].

Technological advances are thus in continuous development to improve surgical tools and methods, with the goal of optimizing the EOR beyond the radiological borders, when functionally possible. Considering recent technical advantages, the aim of this paper is to provide a general overview

SINCh suggestions for Glioma Grade 4 (GG4) management




Fig. 1 GG4 management algorithm proposed by SINCh

of the current trends and technical tools that are available in the management of GG4 surgery (Fig. 1).

The advantages and limitations are highlighted and discussed in compliance with the maximal safe resection principle in glioma surgery. The role of the major treatment modalities of surgery was revised in terms of accuracy and safety.

In addition, the preoperative use of antiepileptic and steroids are discussed according to the current literature.

Materials and methods

The methods used in this systematic review were pre-specified and are presented in accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search was performed using the electronic databases of Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to Present [September 2022]). A top-up search was subsequently performed with the same databases: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to September 24, 2022), with a filter for articles published from 2018 onwards. Medical Subject Heading (MeSH) terms “high grade glioma” “glioblastoma” [MeSH] AND “surg*” [MeSH] and free text terms: “extent of resection” OR “surgery” OR “survival” OR “outcome” OR “surgical planning” OR “preoperative planning” OR “radiotherapy” OR “elderly” OR “intraoperative monitoring” OR “IDH mutation” OR “1p/19q codeletion” OR “tumor grade” OR “MGMT methylation” OR “chemotherapy” OR “adjuvant” OR “recurrence”, were used to ensure the search was as comprehensive as possible. The search strategy that was created, combined the two broad content areas of HGGs, evaluating investigation on intraoperative tools and surgical management.

These two content areas were combined using the Boolean operator “and”. Reference lists of identified studies were also reviewed to identify additional relevant studies.

Inclusion criteria

To be eligible for inclusion in the review, the manuscripts identified had to: report primary data; include adult patients with GG4; and be published in English language. Although the focus of this review is on patients with GG4, the search strategy was deliberately broad to include a range of brain

tumors in order to ensure all studies incorporating patients with gliomas, including studies with mixed pathologies (different types of brain tumors). If there was uncertainty about whether a manuscript was relevant or not, it was decided to include it for full-text review.

Exclusion criteria

The following search results were excluded from this systematic review:

- Review papers, including systematic reviews, meta-analyses, and narrative reviews;
- Single patient case reports (case series or case studies with more than one patient were included);
- Dissertation abstracts;
- Book chapters/books;
- Studies focusing on children, without a predominantly adult population.

Screening process

Manuscript titles were initially screened by 4 authors medically qualified specialists in neurosurgery to identify potentially relevant articles (F.P., F.B., G.C., T.S.). Then, abstracts of screened studies were screened independently by (T.I., P.P.P., G.S., S.S.) to identify relevant studies. Where ambiguity regarding eligibility persisted, the full article was reviewed and disagreements were resolved by consensus.

Data extraction process

Data from studies meeting our inclusion criteria were extracted using a standardized data extraction proforma and critically appraised. The relevant information extracted from the manuscripts included: study setting; study population, participant demographics and baseline characteristics; details of intervention and control conditions, where applicable; study methodology; recruitment and study completion rates; outcomes and times of measurement.

Due to the wide variations in study design and outcome measures, it was not possible to perform a meta-analysis.

A total of 352 potentially relevant studies were identified, including 299 retrospective studies and 53 reviews/meta-analysis (Fig. 2).

The final reference list was then checked by M.M.F., F.F.A., G.S. and F.P. All the authors divided papers to assess several statements as reported in Table 1 and in particular:

Perioperative drugs Management 3 statements, Imaging 3 statements, Surgery 4 statements, Intraoperative imaging 6 statements, Intraoperative treatment options 1 statement, Estimation of extent of tumor resection 3 statements,




Fig. 2 Flowchart of study search and selection

Surgery at tumor progression 1 statement, Surgery in elderly patients 1 statement.

The identification of the statement was performed by M.M.F., A.C. and R.R.

Lastly, two group of authors (T.I., P.P.P., F.P., S.S. and F.F.A, G.S., F.B., V.E.) classified the class of evidence for each statement from Class I to IV, and recommendations were graded Level A (established as effective, data from *multiple RCT (randomized clinical trials) or meta-analyses*), Level B (probably effective, data from: *single RCT or large non-randomized studies*), and Level C (possibly effective, data from *consensus of opinion/experts, small studies, retrospective studies, registries*).

Where ambiguity regarding evidence or recommendation existed, the full process was reviewed and disagreements were resolved by consensus.

The evaluation of the evidence and strength of recommendations for surgical management of gliomas are summarized in Table 1.

Perioperative drugs management

The GG4 clinical onset is extremely variable with subacute presentation, with neurological signs and symptoms progressing over days or weeks. A sudden onset is less common

and associated to epileptic seizure or neurological deficit for intralesional haemorrhage.

The most common presenting symptoms include non-specific symptoms as progressive, fatigue or headache, new-onset epilepsy, focal neurologic signs and mental status alterations in combination with signs of increased intracranial pressure [100]. These symptoms are related to different factors: (1) Tumoral invasion of eloquent brain areas; (2) mass effect by the tumor itself; (3) surrounding tumoral edema [101].

Perioperative medical treatment with steroids, antiepileptic drugs, and antithrombotic prophylaxis is indicated for symptoms relief and prevention of complications. Regarding the antithrombotic prophylaxis the treatment is indicated only in the early postoperative period [102–109].

Treatment of acute venous thromboembolism (VTE) should follow the same protocol as in non-brain tumors, although in high grade gliomas anticoagulant therapy seems to increase by three-fold the risk of hemorrhage, but only with 1% of fatal hemorrhages [110].

Steroid treatment

Tumoral edema is generated by local blood–brain barrier disruption and increased permeability caused by neoangiogenesis [32]. The extent of edema on neuroimaging must be interpreted alongside clinical symptoms, as it not always requires symptomatic treatment. Symptoms related to progressive edema tend to progress with subacute onset and gradual worsening. Systemic glucocorticoids should be considered in all patients who have symptomatic peritumoral edema. The mechanism of action of glucocorticoids for control of vasogenic edema is not fully understood: they are supposed to downregulate the vascular endothelial growth factor (VEGF) and also inhibit production of interleukin 1 (IL-1) [111]. Dexamethasone is considered the standard agent due to its effectiveness and relative lack of mineralocorticoid activity with low potential for fluid retention [30, 112]. In addition, it can be administered orally or intravenously with a 1:1 conversion ratio [113, 114].

The anti-edema effect of dexamethasone is dose-dependent. The starting dose should be individualized based according to edema degree, severity of symptoms and patient weight [112, 115, 116], to optimize the balance between the maximal efficacy and minimum dose-related side effects [32]. Clinical response, rather than radiographic changes, should guide treatments. Most patients improve symptomatically within hours and achieve a maximum benefit from within 24 to 72 h [32]. In general, headache tend to respond better and more quickly than focal deficits. Once patients have responded and stabilized clinically on a given dose, a gradual taper should be attempted [112]. Dose should be reduced every 3–4 days while assessing its efficacy to

Table 1 Summary of Class of Evidence and Strength of Recommendation

Statement	Class of Evidence	Level of Recommendation
<i>Perioperative drugs management</i>		
Glioma patients who never suffered seizures should not be treated with primary prophylaxis with antiseizure medications (ASMs) [25–29]	I	A
Dexamethasone is considered the standard agent due to its high potency and relative lack of mineralocorticoid activity reduce the potential for fluid retention [30–32]	I	A
Anticoagulation with low molecular weight heparin or direct oral anticoagulants for established venous thromboembolism is recommended in patients with primary brain tumors [33]	II	B
<i>Imaging</i>		
The standard protocol includes anatomical, two-dimensional T2-weighted and FLAIR sequences (slice thickness ≤ 4 mm), FLAIR sequences (three-dimensional FLAIR is suggested as an alternative to 2D FLAIR) and three-dimensional T1-weighted images acquired pre- and post-contrast administration [34–36]	II	C
An early postoperative MRI is strongly suggested and should be performed within 48 to 72 hours after surgery, including DWI sequences [37]	II	B
Advanced techniques, such as diffusion MRI (dMRI), perfusion-weighted imaging (PWI), proton magnetic resonance spectroscopy (1HMRS) and positron emission tomography (PET) can provide a visual depiction and quantitative measurement of the pathophysiologic characteristics of the tumor [38, 39]	III	C
PET-CT can provide information about biology, differential diagnosis, delineation of tumor extent for surgical or RT planning, which can be also useful in post-treatment surveillance (progression vs pseudoprogression) [237]		
<i>Surgery</i>		
The extent of surgical resection (EOR) is a strongest independent risk factor for both overall survival (OS) and tumor recurrence [40–43]	II	B
Intraoperative neurophysiological monitoring is associated with lower risk of permanent postoperative deficits and a higher EOR of tumors in eloquent areas [44, 45]	II	B
Cortico-subcortical mapping is the most sensitive and specific technique for the identification of critical cortical hubs and white matter bundles [46, 47]	III	C
Awake surgery can be considered an option, mainly in young patients with lesions in the dominant hemisphere involving language, motor and somato-sensory areas [47–50]	III	C
<i>Intraoperative imaging</i>		
NN: neuro-navigation systems represent the most used intraoperative tool used by neurosurgeons during tumor excision. Based on preoperative imaging, and overlap with FMRI-DTI, neuro-navigation allows preoperative identification of eloquent regions and guides the surgeon during intraoperative mapping and tumor resection [51–56]	III	C
iCT: iCT helped to verify EOR and to identify and resect pathological tissue. iCT represents a feasible and effective alternative for intraoperative updates of the neuro-navigation system [11, 57]	III	C
iUS: iUS is a real-time, accurate and inexpensive imaging method for optimizing the EOR in neurosurgical interventions	III	C
Despite being an operator-dependent method, iUS is associated with a greater EOR and improved PFS and OS in glioma patients [58–60]		
iMRI: iMRI was found to be associated with higher resection rates compared to the neuro-navigated procedures, Unfortunately, the high cost and the need for structural changes in the operating room have limited, to date, the spread of intraoperative MRI [59–64]	III	C
5-ALA: 5-ALA is a metabolic tracer that allows the intraoperative distinction of the boundaries between healthy tissue and tumor near the infiltration zones, thus guiding the glioma resection with an improved intraoperative enhancing vision [65–72]	II	B
Fluorescence: sodium fluorescein (FLCN): The intraoperative guidance determined by FLCN allows to predict histopathological alterations both in areas with contrast enhancement and in the margins of infiltration of the cerebral parenchyma that do not present a neuroimaging contrast [60, 70, 73–76]	III	C
<i>Intraoperative treatment options</i>		
In newly diagnosed HGGs, CWs implantations should not be considered as first-line therapeutic option [77–81]	II	B
<i>Estimation of extent of tumor resection</i>		
The objective estimation of the extent of tumor resection is fundamental in planning postoperative adjuvant treatments, stratifying patients' prognosis and monitoring tumor evolution over time in response to adjuvant treatments [37, 41, 43, 82, 83]	II	B
The volumetric analysis can be carried out by manual segmentation of the areas of interest or by using the so-called ellipsoid volume technique or software with automatic or manual segmentation [82, 84]	III	C

Table 1 (continued)

Statement	Class of Evidence	Level of Recommendation
Stereotactic image-guided brain biopsy is the procedure of choice when an extensive surgical resection is not feasible, as in deep-seated or multifocal tumors, or if the patient has considerable comorbidities increasing the risk of perioperative morbidity or even mortality [85–87]	II	B
<i>Surgery at tumor progression</i>		
The role of second surgery at recurrence is not definitively validated and should be evaluated on individual basis [88–96]	III	C
<i>Surgery in elderly patients</i>		
Thorough evaluation and surgical selection of elderly glioma patients may lead to favorable survival benefit [97–99]	III	C

control symptoms [117]. Slower tapering is necessary after 2–3 weeks of treatment in order to reduce the risk of hypoadrenalism due to hypothalamic axis suppression [32]. Despite their beneficial effect, glucocorticoids are associated with a large number of well-known side effects [113, 118]. Three complications are of particular concern: gastrointestinal complications, steroid myopathy, and opportunistic infections such as *Pneumocystis pneumonia*. In addition, retrospective studies have suggested that the use of steroids may be correlated with decreased overall survival (OS) in glioma patients, independent of potential confounding factors such as tumor size and performance status [32, 119]. If allowed clinically, a maintenance Dexamethasone dose of less than 4 mg per day should be employed [32]. Patients who have undergone only biopsy might need a prolongation of steroids administration in particular when starting of radiotherapy.

Antiseizure medications (ASMs)

Although GG4 are less epileptogenic than lower-grade gliomas, seizures are usually more difficult to control with common ASMs and drug resistance reported in 20% of cases [120–122].

Epileptogenesis in GG4 is partially related to increased intracranial pressure, edema, hypoperfusion, and neoangiogenesis. In addition structural and functional changes in the peritumoral cortex, increased concentrations of cytokines, chemokines, and growth factors contribute both to epileptogenesis and tumor invasiveness [123]. It remains still unclear how the same mechanisms that control tumor behavior may regulate epileptogenesis and how they may influence each other.

Seizure tend to start as focal and may either remain focal or secondarily generalize. Epilepsy should not be considered barely a symptom: it is an important source of morbidity and mortality in patients with brain tumors, and the risk of recurrence is high [124]. Therefore, treatment with a first-line ASM monotherapy at the lowest effective

dose (monitoring serum intervals, if available) is needed. ASMs with no or minimal hepatic enzyme-inducing or -inhibiting properties, such as levetiracetam, pregabalin, lamotrigine, lacosamide, topiramate, are generally preferred, since these agents have a more favourable safety profile [125–130]. Levetiracetam is generally well tolerated but can cause neuropsychiatric side effects, including irritability, agitation, and anxiety especially in patients with frontal lobe tumors [131]. Use of valproate may be associated with a higher rate of hematologic toxicity, leading to CT treatment delays in glioma patients [132]. The initial use of multidrug regimens should be avoided as it decreases the likelihood of compliance, provides a narrower therapeutic window, and is less cost effective. Single ASM treatment has fewer side effects also because drug interactions are avoided. Approximately 50% of patients respond adequately to a single ASM [120]. In case of recurrent seizures after initiation of therapy, doses of the initial agent should be escalated (monitoring serum concentrations) before switching drugs or adding a second agent. If adequate seizure control is not achieved, an alternative or adjunctive ASM should be prescribed. Lacosamide has been increasingly studied as a complementary ASM for HGGs with refractory epilepsy and is generally well tolerated [127, 133].

Twenty-four percent of glioma patients, treated with ASMs, experience side effects that need a change in or discontinuation of antiseizure drug therapy [134], including: rash (especially during RT [135]), drug interactions (e.g., cytochrome P450 induction, increase or decrease of metabolic enzymes for steroids or CT agents).

Prophylactic ASMs are generally not recommended in glioma patients without a history of seizure [25, 26, 136]. Nevertheless, ASM prophylaxis for patients undergoing surgery is advocated by some authors, especially in case of surgery planned with brain mapping. This approach is based on data from observational studies and a limited number of small randomized trials leading to conflicting results [137–146]. The incidence of postoperative seizures

is low (8%) even without prophylactic ASMs, and the incidence of clinically significant seizures is even lower (3%). In contrast, routine administration of ASMs may be associated with significant side effects [142, 143]. If post-operative seizure prophylaxis is employed, ASMs should be gradually tapered beginning one to two weeks after surgery, and then discontinued in patients who remain seizure-free [134].

Antithrombotic treatment

VTE is a common complication in patients with primary brain tumors, with up to 20% of patients per year having a VTE event. Risk factors include patient-related, treatment-related, tumor-related factors, laboratory parameters, and hemostatic biomarkers [147]. Regarding tumor histology, vaso-occlusive and prothrombotic contributions in high-grade gliomas could be underlying necrosis and hypoxia. Indeed, tumor cells pseudo-palisades suggest that this morphologic phenomenon is created by a tumor cell population actively migrating away from a central hypoxic region due to vaso-occlusion caused by intravascular thrombosis. Both vascular endothelial growth factor-induced vascular permeability to plasma coagulation factors and the increased neoplastic expression of tissue factor likely contribute to a prothrombotic state favoring intravascular thrombosis [148]. Furthermore, mutations in the IDH-1 gene correlate with a low incidence of VTE compared to IDH-wild type tumors. In addition, expression of the glycoprotein podoplanin (a platelet activator) on brain tumors was associated with both intratumoral thrombi and a high risk of VTE [147].

Patient-related factors include older age, obesity, dependent functional status (dependency for activities of daily living, and limb paresis). Treatment-related factors include surgery (especially biopsies), subtotal resection, use of corticosteroids, and anti-VEGF therapy. Laboratory parameters and hemostatic biomarkers correlated with a higher risk of VTE are high white blood cell count, low platelet count, high soluble P-selectin levels, elevated coagulation factor VIII activity, and increased D-dimer levels [147, 149].

In other studies, no association between the presence or size of enhancing tumor was not a contraindication for anticoagulation as no difference was found in patients with or without intracerebral hemorrhage (ICH), as well as no correlation between the EOR and the incidence of ICH incidence was found [149].

From a clinical point of view, the management of patients with primary brain tumors and VTE is challenging. Anticoagulation is required to treat patients; however, it is associated with an increased risk of intracranial haemorrhage [147]. For the general cancer population, pharmacological thromboprophylaxis with low-molecular-weight heparin (LMWH) is recommended in hospitalized patients and in

the perioperative setting [150]. As the risk of VTE remains high throughout the course of the disease, a phase III randomized placebo-controlled trial (the PRODIGE study) aimed at evaluating the efficacy and safety of primary thromboprophylaxis with LMWH for up to 12 months in patients with malignant glioma, but the study was terminated early without being able to draw significant conclusions. A trend toward a reduced risk of VTE with heparin (hazard ratio [HR] 0.51, 95% confidence interval [CI]: 0.19–1.4, $p=0.29$) was seen; however, a trend toward increased risk of major bleeding after 12 months was observed with heparin (HR 4.2, 95% CI: 0.48–36, $p=0.22$), and all major bleeds were ICH [102]. Mortality after 12 months was not different between groups. In a meta-analysis involving 539 anticoagulated patients, the authors found that the overall risk for ICH in patients with glioblastoma was more than three-fold higher when receiving anticoagulation in comparison to those who were not receiving anticoagulation; nevertheless, the overall incidence of fatal ICH in this meta-analysis was less than 1% [110]. In the absence of high-quality data, primary pharmacological thromboprophylaxis cannot be recommended for patients with malignant glioma beyond the postoperative period [151]. Another study by Le Rhun et al., including more than 1,000 patients with newly diagnosed glioblastoma, showed that patients with anticoagulants while on radio/chemotherapy had worse survival than patients who did not use them; but patients under anticoagulant therapy mainly used them because of prior VTE events [152]. A meta-analysis of ten randomized controlled studies including 1263 patients with primary brain tumors undergoing craniotomy reported that patients receiving unfractionated heparin alone had a stronger risk reduction in VTE than patients receiving placebo (RR=0.27; 95% CI 0.1–0.73) and heparin with mechanical prophylaxis together showed a lower VTE risk than mechanical prophylaxis alone (RR=0.61; 95% CI 0.46–0.82) [109, 149].

Therefore, based on currently available evidence, in the 2019 updated international clinical practice guidelines for the treatment and prophylaxis of VTE in cancer patients, the use of heparin commenced postoperatively for the prevention of VTE in patients with cancer and undergoing neurosurgery is recommended; primary pharmacological prophylaxis is not recommended for patients with brain tumors not undergoing neurosurgery [33]. This is consistent with the clinical guidance from the International Society on Thrombosis and Hemostasis where no pharmacological prophylaxis is recommended for outpatients with brain tumors [153]. The European Society of Anesthesiology recommends for patients undergoing craniotomy with a high risk of VTE including malignancy, the initiation of mechanical thromboprophylaxis with intermittent pneumatic compression preoperatively in addition to heparin postoperatively as

soon as the bleeding risk is decreased; the thromboprophylaxis is recommended to be continued until discharge [154].

In the case of a VTE event, more-recently-updated guidelines for treating VTE in cancer patients already include the data from randomized controlled studies comparing heparin and direct oral anticoagulants, with the general consensus that anticoagulation should be established with low molecular weight heparin. Anticoagulation should be given for 6 months. Thereafter an individual evaluation should be carried out for each patient including the risk–benefit ratio and tumor activity [33, 155]. Limited data regarding anticoagulation in patients with primary brain tumors leads to uncertainty with regard to which therapy is best for each patient. Current guidelines give support in the treatment of VTE in cancer patients but rarely offer recommendations, especially for brain tumor patients [149]. The American Society of Clinical Oncology states in its recently-published guidelines that in patients with primary brain tumors and VTE, anticoagulation should be offered, but uncertainty remains regarding the choice of agent and patients most likely to benefit [149, 155]. Furthermore, limited safety data is available for the use of direct oral anticoagulants in patients with primary brain tumors [155].

In 2019, the international clinical practice guidelines for the treatment and prophylaxis of VTE in cancer patients recommended anticoagulation for established VTE in patients with primary brain tumors with LMWH or direct oral anticoagulants (grade 2B) [33].

Role of surgery and estimation of the EOR

Modern glioma surgery focuses on the optimal balance between maximal tumor removal and preservation of quality of life [156, 157]. To achieve this goal, considering the infiltrative tumor growing [158], a detailed and personalized anatomic-functional pre-operative planning is fundamental.

Recent investigations have demonstrated the importance of the volumetric estimation of EOR as predictor of survival [8, 159–164].

To reduce the risk of overestimating a residual tumor in consideration of an increased non-specific contrast intake EOR estimation is recommended by using postoperative MRI obtained within 48 h after surgery (at latest within 72 h) [165].

Volumetric image analysis using 3-dimensional measurements should be applied to accurately quantify entire tumour volumes. The volumetric analysis can be carried out by manual segmentation of the areas of interest (ROI, region of interest) on MR images with post-contrast T1, FLAIR or T2 sequences using the DICOM format. The following formula is used to estimate the EOR: “EOR = preoperative

tumor volume – postoperative tumor volume/preoperative tumor volume”.

Alternatively, the so-called ellipsoid volume technique or software with automatic or manual segmentation can be used [84].

The extent of resection should be assessed within 24–48 hours of surgery through MRI (or CT if MRI is not possible), before and after contrast administration; MRI should include diffusion-weighted (DWI) sequences to enable the detection of perioperative ischemia, that eventually enhance after 48 h. If postoperative MRI is performed after 48 h, tissue enhancement may be misinterpreted as a residual tumor, hampering follow-up evaluations. A lesser extent of resection and larger post-surgical residual tumor volumes are negative prognostic factors across gliomas of all grades and subtypes [23, 43, 157, 160, 166–168]. The dilemma regarding the superior predictive value amongst these variables is still open in the field of neuro-oncology.

The definition EOR should include reduction of tumor volume, as a measurement of surgical efficacy, and residual tumor volume (RV), as a measurement of remaining tumor burden [169].

Robust retrospective analysis of prospective data from a randomized trial yielded level IIB evidence that the EOR, maximized by a different combination of intraoperative tools, is positively associated with the OS in GG4 patients [23, 67, 163, 166, 167, 170–172].

In most papers, resection of a GG4 means resection of the contrast-enhancing area. However, nomenclature for definition of EOR achieved in glioma surgery is not standardized yet. A recent review by Karschnia et al. defined six categories for EOR in supratentorial contrast-enhancing glioma: “*supramaximal resection*”, if beyond contrast-enhancing tumor borders (class of evidence III); “*complete resection*”, when EOR corresponds to 100% of contrast-enhancing tumor (class of evidence IIB); “*near total resection*”, if EOR is $\geq 95\%$ contrast-enhancing tumor and $\leq 1 \text{ cm}^3$ residual contrast-enhancing tumor (class of evidence IV); “*subtotal resection*”, in case of $\geq 80\%$ EOR of contrast-enhancing tumor and $\leq 5 \text{ cm}^3$ residual contrast-enhancing tumor (class of evidence IV); “*partial resection*” when EOR is between 1 and 79% contrast-enhancing tumor and/or $> 5 \text{ cm}^3$ residual contrast-enhancing tumor, for mass effect-related symptoms (class of evidence IV); “*biopsy*”, if there is no reduction of tumor volume and performed for tissue-based diagnosis (class of evidence IV) [37].

Traditionally gross total resection (GTR) of post-contrast T1-weighted MRI tumor has been shown to improve OS and progression free survival (PFS) in patients with newly diagnosed GBM compared to subtotal resection (STR) or biopsy in multiple large population studies [23, 166]. However, in recent years, an increasing number of studies have documented that any increase in EOR is correlated to higher

OS and PFS. One of the first papers published by Lacroix on a series of patients with GBM showed that a macroscopic excision greater than 98% of the total lesion correlated with a prolonged survival up to 13 months [23], compared to 8 months in patients with lower EOR values [161].

The early volumetric retrospective investigations suggested that at least 70–78% of the contrast-enhancing tumor volume represented the ideal resection target for survival benefit [84, 118, 173].

In 2016, Brown et al. [43] published a systematic literature review on EOR studies conducted in adult patients with newly diagnosed supratentorial GBMs, including 37 studies, published over the last four decades, with suitable data for meta-analysis (41,117 patients) [43]. Volumetric evaluation of residual tumor was not used in most of them, thus patients were stratified according to the subjective categories “total removal” and “subtotal removal”. Patients who had a GTR, based on the absence of contrast-enhancement on post-op MRIs, had a 61% chance of survival at 1 year after surgery, which was reduced to 19% at 2 years, and were 51% more likely to be free from disease progression at 1 year than those undergoing STR.

In a later retrospective study, Sanai et al. demonstrated a stepwise improvement in OS over 95% ($p < 0.0001$) [174].

The survival benefit resulting from resection of hyperintense FLAIR tumoral signal represent another relevant and debated issue. Recent studies have introduced the concept of “supramaximal resection”, which has been more frequently applied for low grade gliomas including resection of enhancing tumor together with non-enhancing GBM tissue, but the results remain controversial [160, 175]. Altieri et al. suggested that FLAIR-guided EOR does not correlate with patient survival reporting that an EOR > 96% was significantly associated with the prognosis despite a FLAIR-guided wide resection [176]. In line with this investigation, Mampre et al. [177] showed that postoperative residual FLAIR volume was not associated with recurrence and/or survival, neither in patients who underwent GTR of the CE portion of the tumor, nor in STR group. They also proved that CE residual tumor volume is more important than FLAIR volume in terms of recurrence and OS. Conversely, two other studies showed an additional survival benefit when at least part of the T2/FLAIR-hyperintense abnormality was resected [167, 170].

Although current literature strongly supports the role of EOR as independent predictor of OS, underling different survival benefit across the resective categories, recent studies evidenced that the absolute residual tumor volume might be prognostically more relevant than the proportion of removed tumor [37, 160, 169, 178].

That is, a high degree of resection in a large tumor could result in a greater residual tumor mass than a low degree of resection in a small tumor. In accordance to this

consideration, the value of EOR achieved it does not express a direct measure of the residual disease burden, which in turn represents the postsurgical therapeutic target (i.e., radiation therapy and chemotherapy) [160, 169].

In 2022 the international RANO *resect* group published a new classification system for extent of resection in glioblastoma based upon both the relative reduction of tumor volume (in percentage) and the absolute residual tumor volume (in cm³) on postoperative MRI.

The author retrospectively analyzed the volumetric respective data in more than 1000 patients, founding that patients with “maximal CE resection” (class 2) had superior outcome compared to patients with “submaximal CE resection” (class 3) or “biopsy” (class 4). In addition, the authors demonstrated that a removal of non-CE tumor (≤ 5 cm³ residual non-CE tumor) beyond the CE tumor borders may translate into additional survival benefit [178].

Whether it is mainly the degree of EOR or glioma genetic signature to drive prognosis is yet to be defined. Interactions between molecular class and EOR subgroups has been an emerging topic of intense interest. Considering the importance of individual prognostic risk factors and genetic variability of gliomas, it is important to adopt analytic models to establish how these variable hierarchically interact with each other and how they impact survival in the complexity of clinical setting [8].

Tools and strategies to maximize the resection

Over the past two decades, modern pre- and intraoperative imaging techniques, along with surgical tools and developments in monitoring techniques, have improved the potential to achieve a maximal safe resection of glioma [157, 175, 179]. Among neurosurgical centres, different imaging techniques and intraoperative tools are combined, resulting in a wide variety of surgical strategy protocols of proven value in maximizing the EOR [180]. Appropriate and wise integration of those techniques reduces intrinsic shortcomings combining specific strengths aimed at safe glioma resection.

Surgical planning

Many different noninvasive methods may be used for preoperative planning to identify the relationship between glioma and eloquent areas, both at cortical and subcortical level [181].

Preoperative imaging techniques are useful in surgical planning and improve the preoperative communication of surgical risk to patients.

Functional Magnetic Resonance Imaging (fMRI) with Diffusion Tensor Imaging (DTI), fiber tractography and

neuronavigated transcranial magnetic stimulation (nTMS) are widely employed for this purpose [182, 183]. In few centers, positron emission tomography (PET) and Magnetoencephalography (MEG) are also used, even though they are mostly applied in a research setting [184].

fMRI

Functional magnetic resonance techniques allow to establish a functional map of the eloquent regions involved in patients harboring brain tumors [185]. fMRI assesses brain activation by detecting modifications in blood oxygenation level by using the blood oxygen level-dependent (BOLD) contrast [186]. Task-based fMRI is used to localize non-invasively eloquent cortical areas [187]. Resting-state-fMRI is emerging as pre-surgical tool with automatic software for extraction of different networks at the whole brain level [188, 189]. In clinical setting, task-based fMRI compares BOLD signal changes while performing specific tasks to baseline conditions, based on the assumption that increased cerebral blood flow reflects neuronal and synaptic activity [190]. Its major limitation is that even minor alterations in neurovascular coupling, task execution, choice of coefficient correlations threshold (IV) or heterogeneity in data processing can degrade the quality and reliability of the fMRI results [190]. Basically, two groups of tasks and related cortical areas activations are commonly used: motor tasks and language-related tasks [186, 191], although paradigms for identification of visual [192] and sensory [193] areas have also been proposed.

Most studies suggested the feasibility and reliability of motor fMRI in presurgical planning [186], whereas the role of language fMRI is more debated [185, 194]. Indeed, the complexity of network connections related to language function, and the consequently heterogeneous tasks and post-processing techniques, may have a significant impact on the areas identified in language fMRI studies. This complexity and high variability is underlined in the literature reporting highly variable concordance rates, with sensitivity and specificity ranging from 59 to 100% and 0 to 97%, respectively [195, 196].

In patients affected by brain tumors, preoperative task-based fMRI has demonstrated to be a valid and highly sensitive tool for localizing eloquent cortical areas. Nevertheless, its prognostic role both in terms of reduced morbidity and improved oncologic outcome remains not definitively addressed and clarified.

nTMS

Navigated Transcranial magnetic stimulation is being increasingly used for presurgical planning of brain tumors located in eloquent areas [197, 198]. nTMS merges

neurophysiological information with advanced imaging, thus providing a non-invasive preoperative mapping of functional cortical areas. nTMS overlaps the eloquent cortical sites to a 3D rendering of patient's brain MRI, based on navigation, allowing for a customized planning, and anticipating the intraoperative responses of direct electrical stimulation [199]. In particular, nTMS consists in the application of a coil with an electrically induced magnetic field over the patient's head. The magnetic field induces a modification of the neuronal excitability of the cortex, resulting in an excitatory or inhibitory effect that can be measured at a cortical level or recorded at the peripheral muscles [200]. Currently, nTMS excitatory parameters are used for mapping the primary motor cortex through its activation and the recording of motor evoked potentials at the peripheral muscles [201]. Conversely, specific inhibitory stimulation paradigms, based on repetitive nTMS, are used to map complex cognitive functions by evoking a "transient focal inhibition" to the underlying eloquent cortex during a specific task (e.g., object naming), hampering its correct execution. This result confirms the involvement of the inhibited area in the investigated cortical function [201], e.g., language [202]. Some evidences suggest its ability to map also other cognitive functions, including visuospatial skills and executive functions [203–206].

Several studies demonstrated that nTMS mapping of motor and language cortex correlates well with findings obtained by intraoperative direct cortical electrical stimulation [207–209], despite a slightly reduced sensitivity for language [210]. Moreover, several reports demonstrated that nTMS mapping is more reliable than fMRI in the identification of primary motor cortex [211–213], and that the use of nTMS improves motor outcome of patients operated for contrast-enhancing glioma in or close to motor cortex [214–216]. A recent meta-analysis concluded that nTMS motor mapping increases the EOR, improves neurological outcome, and enables a tailored surgical approach for motor-eloquent brain tumors [217].

Finally, nTMS motor mapping can be successfully combined with intraoperative sodium-fluoresceine-guided glioma resection, resulting in increased EOR compared to using fluoresceine alone [218, 219]. Evidences suggest that also nTMS-based language mapping may improve clinical outcome for those lesions located close to the language areas, especially in those not eligible to awake surgery [220–222].

Diffusion imaging with MR tractography

Currently, magnetic resonance tractography represents a unique tool to perform an *in-vivo* depiction of the anatomical course of main white matter fascicles. MR tractography is based on diffusion MR acquisitions that depict and quantify

the anisotropic movement of water along white matter fibers; however, the accuracy of MR tractography is strictly correlated to the specific imaging acquisition protocol used [186]. In the clinical practice, the most used algorithms for image acquisition and reconstruction of white matter bundles are based on Diffusion Tensor Imaging (DTI), usually integrated in the most of the MR scanner and neuro-navigation stations. Therefore, tractography is commonly used for preoperative planning in order to identify the spatial relationship between lesions and surrounding white matter tracts [186, 223–225]. Nevertheless, tractography algorithms suffer from some bias, including the inter-operator variability in selecting anatomical landmarks for tract computation, and reduced accuracy in identification of crossing and ‘kissing’ WM fibers [226–228]. Therefore, new advanced dMRI models and processing algorithms have been developed to solve multiple fiber orientations and to capture complex fiber configurations, thus increasing the accuracy of tractography [229, 230]. In particular, new diffusion MR acquisition protocols such as high angular resolution diffusion-weighted imaging (HARDI) [231, 232] and new probabilistic algorithms such as Constrained Spherical Deconvolution (CSD) and q-ball imaging seem to be more accurate than standard DTI and DSI tractography for planning [233–236]. However, these approaches are less commonly available and require specific post-processing skills. Furthermore, nTMS-based seeding of the standard DTI reconstruction has been recently described. nTMS-based DTI fiber tracking, based on neurophysiological mapping of eloquent cortex, reduces inter-operator variability. Several studies documented a higher accuracy of nTMS-based DTI fiber compared to standard DTI tractography both for reconstruction of motor [183, 226, 237, 238] and language [239–241] tracts. Indeed, the implementation of preoperative nTMS-based tractography in brain tumor surgery resulted in the improvement of patients’ outcome [242–244].

More recently, fMRI-targeted tractography reconstructions of language tracts have been reported as an useful tool to depict the functional subcortical network underlying each fMRI task and the “high-risk subsets” of the subcortical bundles that should be spared during the surgical procedure [245].

Ultimately, by evaluating structural matter changes in combination with the preoperative functional and cognitive assessment, DTI could potentially represent a feasible predictive tool for patient counselling and risk assessment prior to surgery [246, 247].

Intraoperative imaging

Different intraoperative technologies have emerged in recent years with undetermined comparative efficacy in optimizing EOR. An investigation review by Jenkinson et al. [248]

provided low- to very low-evidence in single trial analyses and synthesis of results was not possible.

The effects of image-guided surgery on OS, PFS, and quality of life is demonstrated in large case series [60, 168, 248–254], but a functional comparison is poorly documented [251]. Network and traditional meta-analyses are generally not possible due to high risk of bias, heterogeneity of study population, and variable, not standardized outcome evaluation.

An increasing number of new technologies have been routinely used intraoperatively to enhance tumor visualization and guide the resection. Thus, several biomedical engineering devices aimed at optimizing performance during oncological neurosurgery interventions, such as neuro-navigation systems, intraoperative CT (iCT) and MRI (iMRI), and iUS are available nowadays [175, 180]. Furthermore, gliomas surgery is implemented thanks to the use of fluorophores that allow a better distinction of tumoral tissue from healthy brain tissue compared to microscopic view under white light. The purpose of these methods is to obtain maximal EOR, while preserving neurological functions, especially in cases of neoplasms located in eloquent areas.

Neuronavigation

Among modern tools for resections, neuronavigation systems represent the most used intraoperative tool used by neurosurgeons. Based on preoperative imaging, generally MRI or CT scans, with functional sequences if available, neuro-navigation allows preoperative depiction of the lesion and surrounding anatomical and eloquent structures and guides intraoperative mapping and tumor resection.

Neuronavigation provides intraoperative orientation to the surgeon, helps in planning a precise surgical approach to the targeted lesion, and defines the surrounding neurovascular structures. It has become a mainstream component of the neurosurgical armamentarium and its use leads to improved surgical confidence, accurate bone flap placement, reduced craniotomy size, and anatomical orientation [51, 52]. Incorporation of the functional data provided by fMRI, MR tractography, magnetoencephalography (MEG), or DES atlases with neuronavigation helps to avoid eloquent areas of the brain during surgery [21, 255]. Main limitations of this device are errors during registration, brain shift and local tissue deformation, which reduce the accuracy of real-time neuronavigation [256]. Moreover, integration of tractography into neuronavigation has still a limited value to identify subcortical tracts [159].

Intraoperative MRI

The advantages of using intraoperative MRI (iMRI), compared to the guidance provided by conventional

neuronavigation systems, were highlighted in a recent meta-analysis [62]. iMRI was found to be associated with higher GTR rates compared to neuro-navigated procedures, whereas a substantial difference between the two techniques was not found regarding quality of resection and surgical time. With regards to impact on outcome, use of iMRI has been associated with increased PFS compared to neuronavigation, although OS was similar in the two groups [62].

Moreover, a recent study verified the implementation of the novel Black Blood (BB) imaging technique for intraoperative identification of lack/presence of contrast-enhancing tumor residuals and better delineation of the boundaries of contrast-enhancing malignant tissue. BB imaging is not inferior to conventional turbo field-echo (TFE) imaging for EOR assessment, nonetheless it may significantly reduce iMRI scanning time, whilst increasing diagnostic confidence. Furthermore, given the better depiction of contrast-enhancing tumor residual spread and borders, BB imaging may help improving the degree of glioma resection [61]. Unfortunately, high costs related to structural changes in the operating room to bear the burden of machinery, capital equipment expenses, suite constructions and renovations, and the associated personnel and maintenance costs have limited, to date, the spread of intraoperative MRI.

Intraoperative CT scan

Shalit et al. first described the use of intraoperative CT (iCT) scan for brain tumors in 1979 [257], which represents a further technological improvement introduced in neurosurgery. Several studies have reported its use, documenting its effectiveness and applicability to neurosurgical interventions for different types of lesions [258, 259].

The iCT role in maximizing the EOR has been recently investigated [57]. iCT helped to verify EOR, identify and resect tumor residue also in multifocal tumors. Compared to iMRI, iCT represents a feasible and effective alternative for intraoperative update of neuro-navigation system, providing real-time images, based on its faster execution times. The possibility of contrast administration increases the accuracy of definition of pathological tissue.

Intraoperative ultrasounds (iUS)

iUS is a real-time, accurate and inexpensive imaging method for optimizing EOR in neurosurgical interventions. The main issues of intraoperative iUS use are the choice of the appropriate probe and the interpretation of US images in the three orthogonal planes (axial, sagittal and coronal plane). The difficulties of recognizing regional anatomy can be overcome by practice: training on large number of cases is important to obtain valuable real-time information [249]. Moreover, the possibility of MR and CT-US imaging fusion

for real-time neuronavigation improves the learning curve by help interpreting iUS imaging with the guide of more familiar CT and MR images [260].

A meta-analysis conducted on 790 articles published from 2005 to 2016 documented how use of iUS with contrast administration in glial tumor resection, despite being an operator-dependent method, allowed GTR in 77% of cases and was associated with increased PFS and OS [253].

There are currently no standardized protocols or validated quantitative data guiding the use of iUS. A retrospective study based on quality of resection of intracranial tumors of different types showed that iUS tends to offer dynamic imaging able to correct errors due to anatomical distortion (brain shift and local tissue deformation) in real-time, which conversely limits conventional neuro-navigation systems based on imaging studies performed in the pre-operative phase. Contrast administration provides useful data for intra-operative diagnosis, tissue differentiation and a real-time evaluation of EOR [58]. Further prospective studies are needed to standardize the role of iUS in a neurosurgical setting.

Fluorescence: 5-aminolevulinic acid (5-ALA)

Fluorescence induced by 5-ALA allows, by using a metabolic tracer, intraoperative distinction between healthy tissue and tumor at infiltration margins, thus guiding glioma resection [65, 158, 261, 262].

A multicenter, randomized phase III study on fluorescence guided surgery (FGS) using 5-ALA showed a more complete resections of tumors in enhancing-glioma patients and better patient outcomes than with conventional microsurgery. Complete resection of the enhancing portion of newly diagnosed GG4 occurred in 65% of patients using 5-ALA versus 36% in those assigned to conventional surgery white light group (difference between groups 29% [95% CI 17–40], $p < 0.0001$). In addition to higher rate of complete resections, overall progression-free survival at 6 months (PFS-6) was also significantly greater with 5-ALA FGS (41.0% [32.8–49.2] vs. 21.1% [14.0–28.2]; $p = 0.0003$) [168].

In several studies, it has been shown that tumor resection carried out with the aid of 5-ALA fluorescence is associated with a greater rate of GTR and an increase in PFS [251, 254].

Glioma surgery, especially for lesions harboring in or close to eloquent areas, should respond to two different needs: efficacy in terms of surgical radicality and preservation of neurological function. In a single-center retrospective study [263], the influence on survival with 5-ALA fluorescence for supratentorial gliomas in eloquent areas was evaluated. With the same EOR and OS rates, PFS was

significantly longer in 5-ALA group than in the control group of patients undergoing the white light procedure.

A multimodal approach conjugating 5-ALA for intraoperative visualization of tumor tissue with neurophysiologic cortico-subcortical mapping and monitoring of eloquent areas with fMRI and fiber tracking integrated in neuronavigation system has proven to be useful in improving safety and preserving neurological functions during glioma surgery in eloquent areas, overcoming the advantages obtained with single methods [53].

In the research setting, intraoperative tissue sampling 5ALA guided has been recently proven to be useful in providing insights into the heterogeneity of the spatial glioma microenvironment, underlying the importance to extend the EOR beyond the fluorescence tumor borders when functionally possible [264].

Fluorescence: sodium fluorescein (FLCN)

Recent evidence suggests that intravenous administration of FLCN at induction of anesthesia at a dose of 5 mg/kg represents an important contribution toward maximal resection of GBMs [74, 265, 266].

Intraoperative guidance by FLCN allows to predict histopathological alterations both in areas with contrast enhancement and, with a positive predictive greater than 96%, also at the infiltration non-enhancing margins [73].

FLCN is an easily, available, bio-safe and cheap fluorescein dye FDA approved [65, 267].

The presumed mechanism of action is a passive staining of the extracellular space in areas with disrupted BBB, then it corresponds to gadolinium uptake on magnetic resonance imaging. It implies that the fluorescent area corresponds mainly to enhancing nodule seen at pre-operative MRI T1 after gadolinium administration. Some investigations showed that a SF enhancement could extend beyond gadolinium contrast-enhancing regions, probably because of the smaller molecular weight of SF that allows its diffusion through the damaged BBB.

SF has, however, no specificity for tumor cells in comparison with 5-ALA. Different fluorescence patterns within the tumor are not detectable. The identification of tumor border is thus more difficult and less precise.

Despite these limitations, evident especially in the early use of fluorescein in the FGS, the progressive and extensive use of SF in has led to better exploit all its potentials. Neira et al. demonstrated indeed that intraoperative SF staining correlated with histopathological alteration in both contrast enhancing and non-contrast enhancing regions, with a PPV greater than 96% in non-contrast-enhancing regions, suggesting that SF can be used as a visual marker for glioma resection in both regions of GBM [73].

Brain mapping and neurophysiological monitoring

Although preoperative imaging modalities can facilitate surgical planning, direct cortical and subcortical electrical stimulation remains the gold standard for localizing brain function [268].

More than 50% of GG4 developed near or in eloquent areas. Therefore, when resecting GGS the onco-functional principle of maximal safe resection has to be pursued. In this clinical setting, DES allows the surgeon to prevent damage to eloquent cortical and subcortical areas during re-section, maximizing the EOR in compliance with quality of life preservation [47].

There is compelling evidence that glioma resections using DES are associated with fewer late severe neurologic deficits and more extensive resection [44, 45, 269–271].

Intraoperative neurophysiology offers various stimulation modalities, which efficiency is based on the ability to recognize essential sites with the highest possible resolution.

The bipolar stimulation is the most used technique for cortical and subcortical brain mapping [44, 46, 269, 272, 273]. A growing body of evidence are currently supporting the use of high-frequency monopolar stimulation in glioma surgery [274–276]. The integration of two stimulation paradigms have been recently proposed for intraoperative guidance of motor tumors removal: the 60 Hz-technique [low frequency (LF)] and the pulse-technique [high frequency-(HF)], delivered by bipolar or monopolar probe respectively. The integration of stimulation modalities with clinical context enhances the extent and safety of resection [272].

In addition, motor evoked potentials (MEPs) can be applied to monitor motor function during resection. This may be performed transcranially (tcMEP) or by direct cortical stimulation via a grid or strip electrode (dcMEP) [268, 277].

The above techniques can be used independently or in various combinations. Gogos et al. demonstrated that transcranial and direct cortical MEP monitoring combined with bipolar and monopolar stimulation resulted in improved localization of functional tissue and low rates of transient and permanent deficits [277].

Awake surgery

Brain mapping techniques and awake surgery (AS) represent the gold standard in low grade glioma (LGG) resection [278, 279], whereas the value of AS for GG4 is poorly investigated [20, 48, 49]. A recent meta-analysis based on 53 studies, including 9102 patients, demonstrated that AS and direct electrical stimulation (DES) resulted in an effective surgical strategy even for GG4 in eloquent areas. This intraoperative technical combination provides OS a lower rate of postoperative complications and a higher percentage

of cases with gross total resection, which implies a consequent survival benefit [47]. This technique is usually adopted in younger patients, with circumscribed lesions. Recent volumetric studies demonstrated a negative impact of post-operative T2/FLAIR residual tumor on GG4 OS [160, 280, 281]. Based on these findings, AS may represent an effective surgical approach to safely maximize resection beyond contrast-enhanced tumor area in highly selected cases (collaborative patients without preoperative language deficits harboring lesions in or close to language areas amenable of gross total resection, in the absence of intracranial hypertension). In addition, AS could be useful in association with 5-ALA to detect functions in fluorescent tissue guiding a safe resection [48]. Future perspective investigations are needed to determine efficacy and outcomes of AS in GG4 patients.

Intraoperative treatment options

Carmustine wafers (CWs)

In 2003, the intraoperative treatment with Carmustine Wafers (CWs) implantation [marketed as Gliadel, biodegradable copolymers discs impregnated with the alkylating agent (Bis-ChloroethylNitrosoUrea: BCNU)], for newly high grade glioma was introduced as a therapeutic bridge between the surgical resection and Stupp Protocol onset. The clinical rationale of its development was based on the possibility to locally interfere with the potential tumor re-growth in the proximity of the original tumor site [77, 80, 81].

Different studies demonstrated a promising results in terms of PFS, without detecting a significant survival advantage [79, 282, 283].

A phase 3 study conducted in 14 countries, including the United States, Germany, France, the United Kingdom, Scotland, Finland, and Israel, suggested a prolongation OS in newly diagnosed patients with malignant glioma who received CWs implants. The median OS was 13.9 months for the CWs group and 11.6 months for the placebo-control group (logrank $P=0.03$ stratified by country) [283].

In a later investigation, Pallud et al. designed a largest case-matched analyses on CW implantation efficacy, founding a survival advantage of only 2 months in the implantation group [79].

The elevated costs in addition to the precluded enrolment of patients in subsequent clinical trials, because the use of CW could give rise to confounding results, have led to a gradual abandon of its use after an initial enthusiasm. In addition, in several retrospective studies reported a serious CWs related toxicity, resulting in a delay or precluded Stupp protocol [77, 80].

For all the reasons mentioned above, in newly diagnosed high grade glioma, CWs implantations should not be considered as first-line therapeutic option.

Intraoperative radiotherapy

Adjuvant radiotherapy is considered standard of care in brain malignant gliomas treatment. Recently, in analogy with other cancers, intraoperative radiotherapy (IORT), has been proposed with the aim to provide a boost to standard-of-care external beam radiotherapy (EBRT), in both recurrent and newly diagnosed brain gliomas. Some experiences with IORT have been published lacking in suggesting significant improvement in OS and PFS in both newly diagnosed and recurrent gliomas [284, 285]. A Multicenter Randomized Phase III Trial on INtraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II) is ongoing and will stop recruitment on December 2023. Recently, a pooled analysis has been published suggesting improved efficacy and safety compared to historical control of low energy intraoperative X-ray for newly diagnosed glioblastoma [286].

The role of biopsy

Stereotactic image-guided brain biopsy (SB) is the procedure of choice when an oncologically meaningful surgical resection is not feasible, as in case of deep-seated or multifocal tumors, or if the patient has considerable comorbidities increasing the risk of perioperative morbi-mortality [287, 288]. In such cases, SB is a safe and effective diagnostic technique, with a diagnostic yield of approximately 90% [287, 289, 290].

SB could be performed through frame-based or frameless techniques. Even though frame-based techniques have been considered the “gold standard” for SB as the rigid frame provides excellent targeting precision SB by frameless techniques, also conducted with the assistance of robotic devices, mainly for brainstem or small deep lesions, has gradually replaced the previous one [289, 291]. They showed equal diagnostic yield, in addition to significantly shorter surgical time and less discomfort reported by patients [292].

It is important to note that the tissue size must be adequate to provide MGMT analysis, which could be useful in determining the potential response of chemotherapy treatment, especially in the elderly [293].

Recent coupling with intraoperative MRI systems provides a real-time feedback on targeting [294]. However, no significant differences in diagnostic yield were found compared to neuronavigation on preoperative imaging [290].

Lately, various strategies have been devised to best target the significant portions of the lesions, to enhance the chances of obtaining a clear diagnosis, merging anatomic MRI with multimodal imaging including MRI perfusion and spectroscopy [295, 296] and PET-CT [297, 298].

Perfusion-weighted imaging such as dynamic susceptibility contrast (DSC) MRI measures cerebral blood volume (CBV), which correlates with microvessel density and area. Magnetic resonance spectroscopy (MRS) can detect alterations of metabolite concentrations within the tumor. PET-CT can provide information about biology, differential diagnosis, delineation of tumor extent for surgical and RT planning, which can also be useful in post-treatment surveillance (progression vs pseudoprogression) [237].

Despite being rapid and minimally invasive, SB still poses some risks. Mortality rates reported from large populations studies range from 0.6 to 3.8% [288, 289, 299–302], generally consequent to brain edema or haemorrhage. Deep-seated lesions were found to be associated with higher risk of overall post-operative death, whereas frontotemporal lesions and lymphomas were associated with an increased probability of haemorrhage leading to death [289].

Complications after SB range from 7.4% to 13% and include symptomatic haemorrhage, seizures, infections, change of mental status, and new neurological deficits [289, 299, 302]. Diabetes mellitus and deep-seated lesions appear to increase the risk [302]. Post-operative haemorrhages, in particular, may occur in 7–59.8% of patients; however, only 3.4–5.9% are symptomatic [303, 304]. Biopsy-related haemorrhage risk is higher with hydrocephalus, brain edema, and advanced age [305]. Tumor seeding along the course of the biopsy needle is a rare complication that has been described in the literature [306, 307].

Navigate guided stereotactic systems are recently introduced in routinely neurosurgical practice. Different neuro-navigated systems, such as intraoperative CT scan, MRI or US tools, are progressively applied to a comprehensive range of neurosurgical procedures, including brain tumors surgery. These systems allow a minimally invasive surgical exposure and provides instant and continual navigational information during surgery.

Different studies have shown that these navigate guided systems can reduce operative time, increasing the neurosurgeon's confidence with the anatomic structures of the brain and improving the surgical safety of the biopsy [308].

Finally, deep brain biopsies with accurate tumor localization are made possible by combined use of computerized imaging and stereotactic devices [309].

Second surgery at tumor recurrence

When a signal alteration is documented in follow-up MRI images post-adjuvant therapy, a differential diagnosis should be considered within progression and pseudoprogression. Multi-disciplinary discussion and advanced MRI images could define the real glioma recurrence [310, 311]. It remains unavoidable even if improvements in oncological and surgical treatments may delay this event. The indication to a second surgical operation for HGGs is controversial, in particular regarding selection of patients. In the literature, several variables have been considered to support surgical decision. Reoperation, especially when associated with a favourable preoperative Karnofsky Performance Status (KPS) at recurrence, was regarded as statistically significant variable for improved survival [90, 92, 312–315]. A greater EOR at 1st and 2nd surgery correlate with longer OS [88–92]. Nevertheless, regarding surgical variables, conflicting results have been reported in the literature. Some authors found no significant effect of surgery on survival, or no difference between gross-total resection (GTR) and partial resection [316, 317]. However, there are growing evidences that EOR > 98% at second surgery greatly improve the OS [318, 319]. GTR at second surgery seem to correlate with better OS and post-operative KPS [88–92]. Finally, a benefit is reported in patients with higher KPS score at diagnosis, a greater EOR and initial diagnosis of WHO grade III. About one-third of patients with HGG may be eligible for salvage surgery at the time of progression [320].

Role of systemic therapies at time of recurrence is still debated and standardized protocols are missing, even though recently regorafenib has been included in the NCCN (National Comprehensive Cancer Network) 2021 guidelines as a preferred regimen for recurrent glioblastoma (GB) [321]. Despite randomized trials showing that salvage TMZ before radiation therapy or anti-PD1 immunotherapy before surgery prolong disease-free survival in patients with recurrent GG4 [322–324], combination of surgery and adjuvant therapies with TMZ, fotemustine, carmustine, irinotecan or low-dose fractionated RT has been reported as the best treatment strategy in terms of survival [317]. Administering neoadjuvant therapy before reoperation seems to correlate with poorer KPS, while adjuvant therapy after reoperation is associated with a better OS.

Surgery for recurrent HGG should be carefully evaluated in case of treatment with anti-angiogenic agents (bevacizumab). As a matter of fact, patients receiving bevacizumab are more likely to develop wound complications, CSF leak, infection and osteomyelitis. In case of second surgery for progression during bevacizumab treatment patients exhibit poor prognosis for the increased risk of perioperative complications [325]. If surgery is considered mandatory,

re-operation should be delayed for at least 4 weeks after discontinuing bevacizumab [326].

Regarding patient factors, age < 70 at recurrence confirms as crucial favourable factor [327–329], correlating with OS > 6 months following recurrence. However, KPS at time of recurrence appears to be a stronger factor than age [330]. Indeed, especially if ≥ 90 , it correlates positively with both OS and post-op KPS.

Regarding histological factors, IDH1 mutation is associated with longer survival and improved clinical outcome [331–333]. Nevertheless, despite a globally better clinical course, it is not clear if a correlation with second surgery exists. On the contrary ATRX and PTEN inexpression at first surgery correlates with better KPS and PO.

Nevertheless, these evidences require randomized controlled trials to be confirmed and to support the development of guidelines on management of GG4 recurrence. Surgical indications are still debated, although most studies report improved survival. An adequate patient selection is crucial to achieve the most satisfactory clinical outcome. Given the results of our multicentre retrospective study, a high KPS at recurrence and a GTR following second surgery are pivotal to survival gain and preservation of a high-performance status. Another issue to be explored is the role of early second-look surgery for patients with unintentional incomplete glioblastoma resection detected by early postoperative MRI. Scattered evidence exists of an increased EOR without additional neurological deficit, portending Re-do surgery as a feasible strategy to increase the rate of complete resections in glioblastoma patients [334].

Surgery in elderly glioma patients

GG4 is the most frequent brain tumor in elderly patients (over 70 years), with an incidence rate of 17.5 per 100,000 [335] a poorer prognosis is associated with older age [336], comorbidities, and an intrinsic most aggressive behaviour due to clinical and genetic features [337]. The median survival of elderly patients is approximately six months [338–341], as a result of a debated strategy regarding the optimum management.

Although elderly population is constantly increasing, because of the frailty of elderly and the well-known unfavourable behaviour of GG4 lesions, many neurosurgeons tend to avoid aggressive surgical interventions in this population because of an increased risk of perioperative complications [337, 342].

In recent years, however, there is increasing evidence suggesting that advanced age alone should not necessarily preclude optimal resection followed by adjuvant RT and CT in these patients [337, 342–346].

Standard of care for newly-diagnosed GG4 in elderly patients consists, if feasible, in surgical resection followed by a short course of RT with concomitant and adjuvant TMZ [345].

A latter multicentre investigation demonstrated that surgery can be considered as a first therapeutic option in the workflow of elderly patients, especially when the preoperative estimated EOR is greater than 80% [342].

The OS in elderly patients affected by GG4 is similar to that of younger adults, if factors such as medical comorbidities, effects of general anaesthesia, and vulnerability to postoperative complications, such as delirium, do not overweight the expected clinical benefit. Therefore, a tailored surgical treatment should be carefully planned, according to tumor size and location, patient comorbidities, and preoperative estimation of achievable EOR [347–352]. A thorough evaluation and patients selection are essential to obtain both a favourable survival and functional benefit [337, 342].

Conclusions and future directions

A growing number of evidences support the role of EOR as independent predictor of OS in GG4 patients. The ongoing development of novel intraoperative techniques and strategies for a precise real-time identification of peritumoral functional pathways enables surgeons to maximize EOR minimizing the post-operative morbidity.

Extending the resection according to T2 or FLAIR tumor boundaries implies that functional areas will be encountered. In this clinical setting, DES and brain mapping remain the gold standard technique to detect and monitor the functional networks both at cortical and subcortical level.

Functional MRI and tractography may support the preoperative planning and assist surgeons in selecting the safest surgical approach.

Future prospective randomized clinical trials are needed to compare the influence of the different intraoperative image-guided glioma resection techniques (i.e., NN versus iUS, versus iUS combined with 5-ALA and ore intraoperative neurophysiological monitoring).

The 2021 WHO classification has introduced important changes in each taxonomic category poorly investigated in clinical trials. Future integrative analyses, combining the molecular class according to the 2021 WHO classification and the degree of resection achieved in different MRI sequences, may thus allow a thorough detection of patients with different prognosis, implying a redrawing of the current investigations.

Author contributions Conceptualization: TI, GS, PPP, FFA; Data acquisition: TI, GS, PPP, FFA, FB, GC, SS, TS, FG, FP; Data-quality check: TI, GS, PPP, SS, VE, FP; Writing (original draft): TI, GS, PPP, FFA, FB, GC, SS, FG, FP; Writing (review and editing): TI, GS, PPP, FFA; Validation: GMVB, VE, MS, DG, FD, AD, AG, SG, FP, FS, CS, FS, IM, AR, TS, GP, PM, RB; Supervision: MMF, AC, RR. All authors have read and agreed to the published version of the manuscript.

Funding Open access funding provided by Università degli Studi di Brescia within the CRUI-CARE Agreement. The authors have no competing financial or non-financial interests to disclose.

Data Availability Data regarding screening process are available upon request.

Declarations

Conflict of interest The authors declare no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Deltour I, Poulsen AH, Johansen C et al (2022) Time trends in mobile phone use and glioma incidence among males in the Nordic Countries, 1979–2016. *Environ Int* 168:107487
- Wen PY, Kesari S (2008) Malignant gliomas in adults. *N Engl J Med* 359:492–507
- Stupp R, Brada M, van den Bent MJ et al (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 25:iii93–iii101
- Crocetti E, Trama A, Stiller C et al (2012) Epidemiology of glial and non-glial brain tumours in Europe. *Eur J Cancer* 48:1532–1542
- Ostrom QT, Gittleman H, Xu J et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. *Neuro Oncol* 18:v1–v75
- Kawauchi D, Ohno M, Honda-Kitahara M, et al (2022) The clinical characteristics and outcomes of incidentally discovered glioblastoma. *J Neurooncol*
- Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol* 23:1231–1251
- Ius T, Pignotti F, Della Pepa GM et al (2020) A novel comprehensive clinical stratification model to refine prognosis of glioblastoma patients undergoing surgical resection. *Cancers (Basel)* 12:386
- Lemee JM, Clavreul A, Menei P (2015) Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. *Neuro Oncol* 17:1322–1332
- Ohgaki H (2009) Epidemiology of brain tumors. In: Verma M (ed) *Cancer epidemiology*. Humana Press, Totowa, NJ, pp 323–342
- Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol* 18:170–186
- Brito C, Azevedo A, Esteves S et al (2019) Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. *BMC Cancer* 19:968
- Chen D, Persson A, Sun Y et al (2013) Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis. *PLoS ONE* 8:e61556
- AIOM (2017) Linee guida Neoplasie Cerebrali 2017, p. 1–54
- Oz G, Alger JR, Barker PB et al (2014) Clinical proton MR spectroscopy in central nervous system disorders. *Radiology* 270:658–679
- Kim JY, Park JE, Jo Y et al (2019) Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. *Neuro Oncol* 21:404–414
- Chuang DF, Lin X (2019) Targeted therapies for the treatment of glioblastoma in adults. *Curr Oncol Rep* 21:61
- Brandes AA, Tosoni A, Franceschi E et al (2008) Glioblastoma in adults. *Crit Rev Oncol Hematol* 67:139–152
- Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 10:459–466
- Zigiotto L, Annicchiarico L, Corsini F et al (2020) Effects of supra-total resection in neurocognitive and oncological outcome of high-grade gliomas comparing asleep and awake surgery. *J Neurooncol* 148:97–108
- Sarubbo S, Annicchiarico L, Corsini F et al (2021) planning brain tumor resection using a probabilistic atlas of cortical and sub-cortical structures critical for functional processing: a proof of concept. *Operative Neurosurg* 20:E175–E183
- Katsevman GA, Turner RC, Urhie O et al (2019) Utility of sodium fluorescein for achieving resection targets in glioblastoma: increased gross- or near-total resections and prolonged survival. *J Neurosurg* 132:914–920
- Lacroix M, Abi-Said D, Fournier DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *J Neurosurg* 95:190–198
- Delgado-Lopez PD, Corrales-Garcia EM (2016) Survival in glioblastoma: a review on the impact of treatment modalities. *Clin Transl Oncol* 18:1062–1071
- Sirven JI, Wingerchuk DM, Drazkowski JF et al (2004) Seizure prophylaxis in patients with brain tumors: a meta-analysis. *Mayo Clin Proc* 79:1489–1494
- Tremont-Lukats IW, Ratilal BO, Armstrong T et al (2008) Antiepileptic drugs for preventing seizures in people with brain tumors. *Cochrane Database System Rev* 2010:CD004424
- Garbossa D, Panciani PP, Angeleri R et al (2013) A retrospective two-center study of antiepileptic prophylaxis in patients with surgically treated high-grade gliomas. *Neurol India* 61:131–137
- You G, Sha Z, Jiang T (2020) Clinical diagnosis and perioperative management of glioma-related epilepsy. *Front Oncol* 10:550353

29. Walbert T, Harrison RA, Schiff D et al (2021) SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. *Neuro Oncol* 23:1835–1844
30. Galicich JH, French LA, Melby JC (1961) Use of dexamethasone in treatment of cerebral edema associated with brain tumors. *J Lancet* 81:46–53
31. Kostaras X, Cusano F, Kline GA et al (2014) Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. *Curr Oncol* 21:e493–503
32. Wong ET, Swanson KD (2019) Dexamethasone-friend or foe for patients with glioblastoma? *JAMA Neurol* 76:247–248
33. Farge D, Frere C, Connors JM et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol* 20:e566–e581
34. Ellingson BM, Bendszus M, Boxerman J et al (2015) Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. *Neuro Oncol* 17:1188–1198
35. Bernstock JD, Gary SE, Klinger N et al (2022) Standard clinical approaches and emerging modalities for glioblastoma imaging. *Neurooncol Adv* 4:vdac080
36. Lundy P, Domino J, Ryken T et al (2020) The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update. *J Neurooncol* 150:95–120
37. Karschnia P, Vogelbaum MA, van den Bent M et al (2021) Evidence-based recommendations on categories for extent of resection in diffuse glioma. *Eur J Cancer* 149:23–33
38. Riva M, Lopci E, Gay LG et al (2021) Advancing imaging to enhance surgery: from image to information guidance. *Neurosurg Clin N Am* 32:31–46
39. Albert NL, Weller M, Suchorska B et al (2016) Response assessment in neuro-oncology working group and European Association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro Oncol* 18:1199–1208
40. Lu VM, Goyal A, Graffeo CS et al (2019) Survival benefit of maximal resection for glioblastoma reoperation in the temozolomide era: a meta-analysis. *World Neurosurg* 127:31–37
41. Li XZ, Li YB, Cao Y et al (2017) Prognostic implications of resection extent for patients with glioblastoma multiforme: a meta-analysis. *J Neurosurg Sci* 61:631–639
42. Jackson C, Choi J, Khalafallah AM et al (2020) A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. *J Neurooncol* 148:419–431
43. Brown TJ, Brennan MC, Li M et al (2016) Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. *JAMA Oncol* 2:1460
44. Berger MS, Ojemann GA (1992) Intraoperative brain mapping techniques in neuro-oncology. *Stereotact Funct Neurosurg* 58:153–161
45. De Witt Hamer PC, Robles SG, Zwinderman AH et al (2012) Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. *J Clin Oncol* 30:2559–2565
46. Bello L, Gambini A, Castellano A et al (2008) Motor and language DTI fiber tracking combined with intraoperative subcortical mapping for surgical removal of gliomas. *Neuroimage* 39:369–382
47. Gerritsen JKW, Arends L, Klimek M et al (2019) Impact of intraoperative stimulation mapping on high-grade glioma surgery outcome: a meta-analysis. *Acta Neurochir* 161:99–107
48. Gerritsen JKW, Vietor CL, Rizopoulos D et al (2019) Awake craniotomy versus craniotomy under general anesthesia without surgery adjuncts for supratentorial glioblastoma in eloquent areas: a retrospective matched case-control study. *Acta Neurochir* 161:307–315
49. Zhang JJY, Lee KS, Voisin MR et al (2020) Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis. *Neurooncol Adv* 2:vdad111
50. Pallud J, Dezamis E (2017) Functional and oncological outcomes following awake surgical resection using intraoperative cortico-subcortical functional mapping for supratentorial gliomas located in eloquent areas. *Neurochirurgie* 63:208–218
51. Rasmussen IA Jr, Lindseth F, Rygh OM et al (2007) Functional neuronavigation combined with intra-operative 3D ultrasound: initial experiences during surgical resections close to eloquent brain areas and future directions in automatic brain shift compensation of preoperative data. *Acta Neurochir* 149:365–378
52. Wadley J, Dorward N, Kitchen N et al (1999) Pre-operative planning and intra-operative guidance in modern neurosurgery: a review of 300 cases. *Ann R Coll Surg Engl* 81:217–225
53. Feigl GC, Ritz R, Moraes M et al (2010) Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. *J Neurosurg* 113:352–357
54. Kuhn SA, Romeike B, Walter J et al (2009) Multiplanar MRI-CT fusion neuronavigation-guided serial stereotactic biopsy of human brain tumors: proof of a strong correlation between tumor imaging and histopathology by a new technical approach. *J Cancer Res Clin Oncol* 135:1293–1302
55. Willems PW, Taphoorn MJ, Burger H et al (2006) Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. *J Neurosurg* 104:360–368
56. Wirtz CR, Albert FK, Schwaderer M et al (2000) The benefit of neuronavigation for neurosurgery analyzed by its impact on glioblastoma surgery. *Neurol Res* 22:354–360
57. Barbagallo GMV, Palmucci S, Visocchi M et al (2016) Portable intraoperative computed tomography scan in image-guided surgery for brain high-grade gliomas: analysis of technical feasibility and impact on extent of tumor resection. *Operative neurosurgery* 12:19–30
58. Lekht I, Brauner N, Bakhsheshian J et al (2016) Versatile utilization of real-time intraoperative contrast-enhanced ultrasound in cranial neurosurgery: technical note and retrospective case series. *Neurosurg Focus* 40:E6
59. Coburger J, Scheuerle A, Kapapa T et al (2015) Sensitivity and specificity of linear array intraoperative ultrasound in glioblastoma surgery: a comparative study with high field intraoperative MRI and conventional sector array ultrasound. *Neurosurg Rev* 38:499–509
60. Eljamel MS, Mahboob SO (2016) The effectiveness and cost-effectiveness of intraoperative imaging in high-grade glioma resection; a comparative review of intraoperative ALA, fluorescein, ultrasound and MRI. *Photodiagn Photodyn Ther* 16:35–43
61. Finck T, Gempt J, Krieg SM et al (2020) Assessment of the extent of resection in surgery of high-grade glioma-evaluation of black blood sequences for intraoperative magnetic resonance imaging at 3 Tesla. *Cancers (Basel)* 12:1580
62. Li P, Qian R, Niu C et al (2017) Impact of intraoperative MRI-guided resection on resection and survival in patient with gliomas: a meta-analysis. *Curr Med Res Opin* 33:621–630
63. Kubben PL, ter Meulen KJ, Schijns OE et al (2011) Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. *Lancet Oncol* 12:1062–1070
64. Lo YT, Lee H, Shui C et al (2021) Intraoperative magnetic resonance imaging for low-grade and high-grade gliomas: what is the evidence? A meta-analysis. *World Neurosurg* 149:232–243
65. La Rocca G, Della Pepa GM, Menna G et al (2019) State of the art of fluorescence guided techniques in neurosurgery. *J Neurosurg Sci* 63:619–624

66. Pichlmeier U, Bink A, Schackert G et al (2008) Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. *Neuro Oncol* 10:1025–1034
67. Stummer W, Reulen HJ, Meinel T et al (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. *Neurosurgery* 62:564–576
68. Diez Valle R, Tejada Solis S, Idoate Gastearena MA et al (2011) Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. *J Neurooncol* 102:105–113
69. Gandhi S, Tayebi Meybodi A, Belykh E et al (2019) Survival outcomes among patients with high-grade glioma treated with 5-aminolevulinic acid-guided surgery: a systematic review and meta-analysis. *Front Oncol* 9:620
70. Mazurek M, Kulesza B, Stoma F et al (2020) Characteristics of fluorescent intraoperative dyes helpful in gross total resection of high-grade gliomas—a systematic review. *Diagnostics* 10:1100
71. Eatz TA, Eichberg DG, Lu VM et al (2022) Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review. *J Neurooncol* 156:233–256
72. Eljamel S (2015) 5-ALA fluorescence image guided resection of glioblastoma multiforme: a meta-analysis of the literature. *Int J Mol Sci* 16:10443–10456
73. Neira JA, Ung TH, Sims JS et al (2017) Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance. *J Neurosurg* 127:111–122
74. Acerbi F, Broggi M, Eoli M et al (2014) Is fluorescein-guided technique able to help in resection of high-grade gliomas? *Neurosurg Focus* 36:E5
75. Nikova AS, Vlotinou P, Karelis L et al (2022) Gross total resection with fluorescence could lead to improved overall survival rates: a systematic review and meta-analysis. *Br J Neurosurg* 36:316–322
76. Acerbi F, Cavallo C, Broggi M et al (2014) Fluorescein-guided surgery for malignant gliomas: a review. *Neurosurg Rev* 37:547–557
77. Ius T, Cesselli D, Isola M et al (2018) Combining clinical and molecular data to predict the benefits of carmustine wafers in newly diagnosed high-grade gliomas. *Curr Treat Options Neurol* 20:3
78. Ius T, Pignotti F, Della Pepa GM et al (2022) Glioblastoma: from volumetric analysis to molecular predictors. *J Neurosurg Sci* 66:173–186
79. Pallud J, Audureau E, Noel G et al (2015) Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. *Neuro Oncol* 17:1609–1619
80. Ricciardi L, Manini I, Cesselli D et al (2022) Carmustine wafers implantation in patients with newly diagnosed high grade glioma: is it still an option? *Front Neurol* 13:884158
81. Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro Oncol* 22:1073–1113
82. Bette S, Barz M, Wiestler B et al (2018) Prognostic value of tumor volume in glioblastoma patients: size also matters for patients with incomplete resection. *Ann Surg Oncol* 25:558–564
83. Wang L, Liang B, Li YI et al (2019) What is the advance of extent of resection in glioblastoma surgical treatment—a systematic review. *Chinese neurosurgical journal* 5:2
84. Zeppa P, Neitzert L, Mammi M et al (2020) How reliable are volumetric techniques for high-grade gliomas? A comparison study of different available tools. *Neurosurgery* 87:E672–E679
85. Eigenbrod S, Trabold R, Brucker D et al (2014) Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. *Acta Neurochir* 156:1427–1440
86. Hamisch CA, Minartz J, Blau T et al (2019) Frame-based stereotactic biopsy of deep-seated and midline structures in 511 procedures: feasibility, risk profile, and diagnostic yield. *Acta Neurochir* 161:2065–2071
87. Shooman D, Belli A, Grundy PL (2010) Image-guided frameless stereotactic biopsy without intraoperative neuropathological examination. *J Neurosurg* 113:170–178
88. Coburger J, Wirtz CR, König RW (2017) Impact of extent of resection and recurrent surgery on clinical outcome and overall survival in a consecutive series of 170 patients for glioblastoma in intraoperative high field magnetic resonance imaging. *J Neurosurg Sci* 61:233–244
89. Delgado-Fernandez J, Garcia-Pallero MA, Blasco G et al (2017) Usefulness of reintervention in recurrent glioblastoma: an indispensable weapon for increasing survival. *World Neurosurg* 108:610–617
90. Perrini P, Gambacciani C, Weiss A et al (2017) Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis. *J Neurooncol* 131:585–591
91. Quick J, Gessler F, Dutzmann S et al (2014) Benefit of tumor resection for recurrent glioblastoma. *J Neurooncol* 117:365–372
92. Wann A, Tully PA, Barnes EH et al (2018) Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study. *J Neurooncol* 137:409–415
93. Botros D, Dux H, Price C et al (2021) Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review. *Neurosurg Rev* 44:1259–1271
94. Lu VM, Jue TR, McDonald KL et al (2018) The survival effect of repeat surgery at glioblastoma recurrence and its trend: a systematic review and meta-analysis. *World Neurosurg* 115:453–459
95. McBain C, Lawrie TA, Rogozinska E et al (2021) Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. *Cochrane Database System Rev* 5:CD013579
96. Ryken TC, Kalkanis SN, Buatti JM et al (2014) The role of cytoreductive surgery in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 118:479–488
97. Asmaa A, Dixit S, Rowland-Hill C et al (2018) Management of elderly patients with glioblastoma-multiforme—a systematic review. *Br J Radiol* 91:20170271
98. Hanna C, Lawrie TA, Rogozinska E et al (2020) Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. *Cochrane Database System Rev* 3:CD013261
99. Zarnett OJ, Sahgal A, Gosio J et al (2015) Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. *JAMA Neurol* 72:589–596
100. McKinnon C, Nandhabalan M, Murray SA et al (2021) Glioblastoma: clinical presentation, diagnosis, and management. *BMJ* 374:n1560
101. Chang SM, Parney IF, Huang W et al (2005) Patterns of care for adults with newly diagnosed malignant glioma. *JAMA* 293:557–564
102. Perry JR, Julian JA, Laperriere NJ et al (2010) PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. *J Thrombosis Haemostasis* 8:1959–1965
103. Schmidt F, Faul C, Dichgans J et al (2002) Low molecular weight heparin for deep vein thrombosis in glioma patients. *J Neurol* 249:1409–1412
104. Agnelli G, Piovella F, Buoncristiani P et al (1998) Enoxaparin plus compression stockings compared with compression

- stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med* 339:80–85
105. Iorio A, Agnelli G (2000) Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. *Arch Intern Med* 160:2327–2332
 106. Turpie AG, Gallus A, Beattie WS et al (1977) Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. *Neurology* 27:435–438
 107. Constantini S, Kanner A, Friedman A et al (2001) Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. *J Neurosurg* 94:918–921
 108. Gerber DE, Segal JB, Salhotra A et al (2007) Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis. *Cancer* 109:300–305
 109. Alshehri N, Cote DJ, Hulou MM et al (2016) Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis. *J Neurooncol* 130:561–570
 110. Zwicker JI, Karp Leaf R, Carrier M (2016) A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. *J Thromb Haemost* 14:1736–1740
 111. Herting CJ, Chen Z, Maximov V et al (2019) Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema. *Brain* 142:3834–3851
 112. Chang SM, Messersmith H, Ahluwalia M et al (2019) Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines. *Neuro Oncol* 21:424–427
 113. Dekker M (1995) Use of glucocorticoids in neuro-oncology. In: *Neurological complications of cancer*. New York, p. 199
 114. Lim-Fat MJ, Bi WL, Lo J et al (2019) Letter: when less is more: dexamethasone dosing for brain tumors. *Neurosurgery* 85:E607–E608
 115. Vecht CJ, Hovestadt A, Verbiest HB et al (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. *Neurology* 44:675–680
 116. Ryken TC, McDermott M, Robinson PD et al (2010) The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 96:103–114
 117. Kaal EC, Vecht CJ (2004) The management of brain edema in brain tumors. *Curr Opin Oncol* 16:593–600
 118. Henker C, Kriesen T, Glass A et al (2017) Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival. *J Neurooncol* 135:391–402
 119. Pitter KL, Tamagno I, Alikhanyan K et al (2016) Corticosteroids compromise survival in glioblastoma. *Brain* 139:1458–1471
 120. van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. *Lancet Neurol* 6:421–430
 121. Ruda R, Bello L, Duffau H et al (2012) Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. *Neuro Oncol* 14(Suppl 4):iv55–64
 122. Rossi J, Cavallieri F, Biagini G et al (2022) Epileptogenesis and tumorigenesis in glioblastoma: which relationship? *Medicina* 58:1349
 123. Radin DP, Tsirka SE (2020) Interactions between tumor cells, neurons, and microglia in the glioma microenvironment. *Int J Mol Sci* 21
 124. Rossetti AO, Stupp R (2010) Epilepsy in brain tumor patients. *Curr Opin Neurol* 23:603–609
 125. Rosati A, Buttolo L, Stefani R et al (2010) Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. *Arch Neurol* 67:343–346
 126. Usery JB, Michael LM 2nd, Sills AK et al (2010) A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. *J Neurooncol* 99:251–260
 127. Maschio M, Dinapoli L, Gomellini S et al (2010) Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. *J Neurooncol* 98:109–116
 128. Saria MG, Corle C, Hu J et al (2013) Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. *J Neurosurg* 118:1183–1187
 129. Rossetti AO, Jeckelmann S, Novy J et al (2014) Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors: a phase II randomized study. *Neuro Oncol* 16:584–588
 130. Maschio M, Pauletto G, Zarabla A et al (2019) Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis. *Int J Neurosci* 129:593–597
 131. Bedetti C, Romoli M, Maschio M et al (2017) Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. *Eur J Neurol* 24:1283–1289
 132. Acharya S, Bussel JB (2000) Hematologic toxicity of sodium valproate. *J Pediatr Hematol Oncol* 22:62–65
 133. Ruda R, Pellerino A, Franchino F et al (2018) Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. *J Neurooncol* 136:105–114
 134. Glantz MJ, Cole BF, Forsyth PA et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 54:1886–1893
 135. Mamon HJ, Wen PY, Burns AC et al (1999) Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. *Epilepsia* 40:341–344
 136. Mikkelsen T, Paleologos NA, Robinson PD et al (2010) The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 96:97–102
 137. Milligan TA, Hurwitz S, Bromfield EB (2008) Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. *Neurology* 71:665–669
 138. Lwu S, Hamilton MG, Forsyth PA et al (2010) Use of perioperative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. *J Neurooncol* 96:403–408
 139. Sughrue ME, Rutkowski MJ, Chang EF et al (2011) Postoperative seizures following the resection of convexity meningiomas: are prophylactic anticonvulsants indicated? Clinical article. *J Neurosurg* 114:705–709
 140. Kuijlen JM, Teernstra OP, Kessels AG et al (1996) Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. *Seizure* 5:291–298
 141. Zachenhofer I, Donat M, Oberndorfer S et al (2011) Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. *J Neurooncol* 101:101–106
 142. Komotar RJ, Raper DM, Starke RM et al (2011) Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy. *J Neurosurg* 115:483–490
 143. Wu AS, Trinh VT, Suki D et al (2013) A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. *J Neurosurg* 118:873–883
 144. Fuller KL, Wang YY, Cook MJ et al (2013) Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous

- and total prophylactic regimen among craniotomy patients: a prospective randomized study. *Epilepsia* 54:45–57
145. Chandra V, Rock AK, Opalak C et al (2017) A systematic review of perioperative seizure prophylaxis during brain tumor resection: the case for a multicenter randomized clinical trial. *Neurosurg Focus* 43:E18
 146. Greenhalgh J, Weston J, Dundar Y et al (2020) Antiepileptic drugs as prophylaxis for postcraniotomy seizures. *Cochrane Database System Rev* 4:CD007286
 147. Riedl J, Ay C (2019) Venous thromboembolism in brain tumors: risk factors, molecular mechanisms, and clinical challenges. *Semin Thromb Hemost* 45:334–341
 148. Brat DJ, Van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. *Lab Invest* 84:397–405
 149. Muster V, Gary T (2020) Incidence, therapy, and bleeding risk-cancer-associated thrombosis in patients with glioblastoma. *Cancers (Basel)* 12:1354
 150. Lyman GH, Bohlke K, Khorana AA et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. *J Clin Oncol* 33:654–656
 151. Jo JT, Schiff D, Perry JR (2014) Thrombosis in brain tumors. *Semin Thromb Hemost* 40:325–331
 152. Le Rhun E, Genbrugge E, Stupp R et al (2018) Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. *Eur J Cancer* 101:95–104
 153. Khorana AA, Otten HM, Zwicker JJ et al (2014) Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. *J Thromb Haemost* 12:1928–1931
 154. Faraoni D, Comes RF, Geerts W et al (2018) European guidelines on perioperative venous thromboembolism prophylaxis: Neurosurgery. *Eur J Anaesthesiol* 35:90–95
 155. Key NS, Khorana AA, Kuderer NM et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. *J Clin Oncol* 38:496–520
 156. Revilla-Pacheco F, Rodriguez-Salgado P, Barrera-Ramirez M et al (2021) Extent of resection and survival in patients with glioblastoma multiforme: systematic review and meta-analysis. *Medicine* 100:e26432
 157. Sanai N, Berger MS (2018) Surgical oncology for gliomas: the state of the art. *Nat Rev Clin Oncol* 15:112–125
 158. Altieri R, Barbagallo D, Certo F et al (2021) Peritumoral microenvironment in high-grade gliomas: from FLAIRectomy to microglia-glioma cross-talk. *Brain sciences* 11:200
 159. Almeida JP, Chaichana KL, Rincon-Torroella J et al (2015) The value of extent of resection of glioblastomas: clinical evidence and current approach. *Curr Neurol Neurosci Rep* 15:517
 160. Molinaro AM, Hervey-Jumper S, Morshed RA et al (2020) Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. *JAMA Oncol* 6:495–503
 161. Openlander ME, Wolf AB, Snyder LA et al (2014) An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. *J Neurosurg* 120:846–853
 162. Roder C, Bisdas S, Ebner FH et al (2014) Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. *Eur J Surg* 40:297–304
 163. Sanai N, Polley MY, McDermott MW et al (2011) An extent of resection threshold for newly diagnosed glioblastomas. *J Neurosurg* 115:3–8
 164. Sezer S, van Amerongen MJ, Delye HHK et al (2020) Accuracy of the neurosurgeons estimation of extent of resection in glioblastoma. *Acta Neurochir* 162:373–378
 165. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol* 28:1963–1972
 166. McGirt MJ, Chaichana KL, Gathinji M et al (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. *J Neurosurg* 110:156–162
 167. Li YM, Suki D, Hess K et al (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? *J Neurosurg* 124:977–988
 168. Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol* 7:392–401
 169. Grabowski MM, Recinos PF, Nowacki AS et al (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. *J Neurosurg* 121:1115–1123
 170. Pessina F, Navarria P, Cozzi L et al (2017) Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. *J Neurooncol* 135:129–139
 171. Schupper AJ, Yong RL, Hadjipanayis CG (2021) The neurosurgeon's armamentarium for gliomas: an update on intraoperative technologies to improve extent of resection. *J Clin Med* 10:236
 172. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 352:987–996
 173. Keles GE, Lamborn KR, Chang SM et al (2004) Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. *J Neurosurg* 100:41–46
 174. Sanai N, Berger MS (2011) Extent of resection influences outcomes for patients with gliomas. *Revue Neurologique* 167:648–654
 175. Certo F, Altieri R, Maione M et al (2021) FLAIRectomy in supramarginal resection of glioblastoma correlates with clinical outcome and survival analysis: a prospective, single institution, case series. *Operat Neurosurg* 20:151–163
 176. Altieri R, Melcarne A, Soffietti R et al (2019) Supratotal resection of glioblastoma: is less more? *Surg Technol Int* 35:432–440
 177. Mampre D, Ehresman J, Pinilla-Monsalve G et al (2018) Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes. *Br J Neurosurg* 32:528–535
 178. Karschnia P, Young JS, Dono A et al (2022) Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. *J Neuro Oncol*. https://doi.org/10.1200/JCO.2022.40.16_suppl.2003
 179. Mazzucchi E, La Rocca G, Ius T et al (2020) Multimodality imaging techniques to assist surgery in low-grade gliomas. *World Neurosurg* 133:423–425
 180. Barbagallo G, Maione M, Peschillo S et al (2019) Intraoperative computed tomography, navigated ultrasound, 5-amino-levulinic acid fluorescence and neuromonitoring in brain tumor surgery: overtreatment or useful tool combination? *J Neurosurg Sci*. <https://doi.org/10.23736/S0390-5616.19.04735-0>
 181. Roland JL, Hacker CD, Leuthardt EC (2020) A review of passive brain mapping techniques in neurological surgery. *Neurosurgery* 88:15–24
 182. Spena G, Nava A, Cassini F et al (2010) Preoperative and intraoperative brain mapping for the resection of eloquent-area tumors: a prospective analysis of methodology, correlation, and usefulness based on clinical outcomes. *Acta Neurochir* 152:1835–1846

183. Raffa G, Conti A, Scibilia A et al (2017) Functional reconstruction of motor and language pathways based on navigated transcranial magnetic stimulation and DTI fiber tracking for the preoperative planning of low grade glioma surgery: a new tool for preservation and restoration of eloquent networks. *Acta Neurochir Suppl* 124:251–261
184. Steinmeier R, Sobottka SB, Reiss G et al (2002) Surgery of low-grade gliomas near speech-eloquent regions: brainmapping versus preoperative functional imaging. *Onkologie* 25:552–557
185. Manan HA, Franz EA, Yahya N (2020) Utilization of functional MRI language paradigms for pre-operative mapping: a systematic review. *Neuroradiology* 62:353–367
186. Castellano A, Cirillo S, Bello L et al (2017) Functional MRI for surgery of gliomas. *Curr Treat Options Neurol* 19:34
187. Bizzi A, Blasi V, Falini A et al (2008) Presurgical functional MR imaging of language and motor functions: validation with intraoperative electrocortical mapping. *Radiology* 248:579–589
188. Zaca D, Corsini F, Rozzanigo U et al (2018) Whole-brain network connectivity underlying the human speech articulation as emerged integrating direct electric stimulation, resting state fmri and tractography. *Front Hum Neurosci* 12:405
189. Zaca D, Jovicich J, Corsini F et al (2018) ReStNeuMap: a tool for automatic extraction of resting-state functional MRI networks in neurosurgical practice. *J Neurosurg* 131:764–771
190. Silva MA, See AP, Essayed WI et al (2018) Challenges and techniques for presurgical brain mapping with functional MRI. *NeuroImage Clin* 17:794–803
191. Black DF, Vachha B, Mian A et al (2017) American society of functional neuroradiology-recommended fMRI paradigm algorithms for presurgical language assessment. *AJNR Am J Neuroradiol* 38:E65–E73
192. DeYoe EA, Raut RV (2014) Visual mapping using blood oxygen level dependent functional magnetic resonance imaging. *Neuroimaging Clin N Am* 24:573–584
193. Pujol J, Deus J, Acebes JJ et al (2008) Identification of the sensorimotor cortex with functional MRI: frequency and actual contribution in a neurosurgical context. *J Neuroimaging* 18:28–33
194. Bizzi A (2009) Presurgical mapping of verbal language in brain tumors with functional MR imaging and MR tractography. *Neuroimaging Clin N Am* 19:573–596
195. Kuchcinski G, Mellerio C, Pallud J et al (2015) Three-tesla functional MR language mapping: comparison with direct cortical stimulation in gliomas. *Neurology* 84:560–568
196. Giussani C, Roux FE, Ojemann J et al (2010) Is preoperative functional magnetic resonance imaging reliable for language areas mapping in brain tumor surgery? Review of language functional magnetic resonance imaging and direct cortical stimulation correlation studies. *Neurosurgery* 66:113–120
197. Lefaucheur JP, Picht T (2016) The value of preoperative functional cortical mapping using navigated TMS. *Neurophysiologie Clinique/Clin Neurophysiol* 46:125–133
198. Rizzo V, Terranova C, Conti A et al (2014) Preoperative functional mapping for rolandic brain tumor surgery. *Neurosci Lett* 583:136–141
199. Raffa G, Quattropiani MC, Germano A (2019) When imaging meets neurophysiology: the value of navigated transcranial magnetic stimulation for preoperative neurophysiological mapping prior to brain tumor surgery. *Neurosurg Focus* 47:E10
200. Rossini PM, Barker AT, Berardelli A et al (1994) Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. *Electroencephalogr Clin Neurophysiol* 91:79–92
201. Krieg SM, Lioumis P, Makela JP et al (2017) Protocol for motor and language mapping by navigated TMS in patients and healthy volunteers; workshop report. *Acta Neurochir* 159:1187–1195
202. Lioumis P, Zhdanov A, Makela N et al (2012) A novel approach for documenting naming errors induced by navigated transcranial magnetic stimulation. *J Neurosci Methods* 204:349–354
203. Giglhuber K, Maurer S, Zimmer C et al (2017) Evoking visual neglect-like deficits in healthy volunteers—an investigation by repetitive navigated transcranial magnetic stimulation. *Brain Imaging Behav* 11:17–29
204. Giglhuber K, Maurer S, Zimmer C et al (2018) Mapping visuospatial attention: the greyscales task in combination with repetitive navigated transcranial magnetic stimulation. *BMC Neurosci* 19:40
205. Hannula H, Neuvonen T, Savolainen P et al (2010) Increasing top-down suppression from prefrontal cortex facilitates tactile working memory. *Neuroimage* 49:1091–1098
206. Maurer S, Tanigawa N, Sollmann N et al (2016) Non-invasive mapping of calculation function by repetitive navigated transcranial magnetic stimulation. *Brain Struct Funct* 221:3927–3947
207. Picht T, Krieg SM, Sollmann N et al (2013) A comparison of language mapping by preoperative navigated transcranial magnetic stimulation and direct cortical stimulation during awake surgery. *Neurosurgery* 72:808–819
208. Picht T, Schmidt S, Brandt S et al (2011) Preoperative functional mapping for rolandic brain tumor surgery: comparison of navigated transcranial magnetic stimulation to direct cortical stimulation. *Neurosurgery* 69:581–588
209. Zdunczyk A, Fleischmann R, Schulz J et al (2013) The reliability of topographic measurements from navigated transcranial magnetic stimulation in healthy volunteers and tumor patients. *Acta Neurochir* 155:1309–1317
210. Krieg SM, Sollmann N, Tanigawa N et al (2016) Cortical distribution of speech and language errors investigated by visual object naming and navigated transcranial magnetic stimulation. *Brain Struct Funct* 221:2259–2286
211. Mangraviti A, Casali C, Cordella R et al (2013) Practical assessment of preoperative functional mapping techniques: navigated transcranial magnetic stimulation and functional magnetic resonance imaging. *Neurol Sci* 34:1551–1557
212. Coburger J, Musahl C, Henkes H et al (2013) Comparison of navigated transcranial magnetic stimulation and functional magnetic resonance imaging for preoperative mapping in rolandic tumor surgery. *Neurosurg Rev* 36:65–75
213. Forster MT, Hattingen E, Senft C et al (2011) Navigated transcranial magnetic stimulation and functional magnetic resonance imaging: advanced adjuncts in preoperative planning for central region tumors. *Neurosurgery* 68:1317–1324
214. Frey D, Schilt S, Strack V et al (2014) Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations. *Neuro Oncol* 16:1365–1372
215. Krieg SM, Sabih J, Bulbasova L et al (2014) Preoperative motor mapping by navigated transcranial magnetic brain stimulation improves outcome for motor eloquent lesions. *Neuro Oncol* 16:1274–1282
216. Picht T, Frey D, Thieme S et al (2016) Presurgical navigated TMS motor cortex mapping improves outcome in glioblastoma surgery: a controlled observational study. *J Neurooncol* 126:535–543
217. Raffa G, Scibilia A, Conti A et al (2019) The role of navigated transcranial magnetic stimulation for surgery of motor-eloquent brain tumors: a systematic review and meta-analysis. *Clin Neurol Neurosurg* 180:7–17
218. Raffa G, Picht T, Angileri FF et al (2019) Surgery of malignant motor-eloquent gliomas guided by sodium-fluorescein and

- navigated transcranial magnetic stimulation: a novel technique to increase the maximal safe resection. *J Neurosurg Sci* 63:670–678
219. Raffa G, Scibilia A, Conti A et al (2019) Multimodal surgical treatment of high-grade gliomas in the motor area: the impact of the combination of navigated transcranial magnetic stimulation and fluorescein-guided resection. *World Neurosurg* 128:e378–e390
 220. Ille S, Sollmann N, Butenschoen VM et al (2016) Resection of highly language-eloquent brain lesions based purely on rTMS language mapping without awake surgery. *Acta Neurochir* 158:2265–2275
 221. Raffa G, Quattropiani MC, Scibilia A et al (2018) Surgery of language-eloquent tumors in patients not eligible for awake surgery: the impact of a protocol based on navigated transcranial magnetic stimulation on presurgical planning and language outcome, with evidence of tumor-induced intra-hemispheric plasticity. *Clin Neurol Neurosurg* 168:127–139
 222. Sollmann N, Ille S, Hauck T et al (2015) The impact of preoperative language mapping by repetitive navigated transcranial magnetic stimulation on the clinical course of brain tumor patients. *BMC Cancer* 15:261
 223. Catani M, Howard RJ, Pajevic S et al (2002) Virtual in vivo interactive dissection of white matter fasciculi in the human brain. *Neuroimage* 17:77–94
 224. ffytche DH, Catani M (2005) Beyond localization: from hodology to function. *Phil Trans R Soc Lond B Biol Sci* 360:767–779
 225. Vanderweyen DC, Theaud G, Sidhu J et al (2020) The role of diffusion tractography in refining glial tumor resection. *Brain Struct Funct* 225:1413–1436
 226. Conti A, Raffa G, Granata F et al (2014) Navigated transcranial magnetic stimulation for “somatotopic” tractography of the corticospinal tract. *Neurosurgery* 10(Suppl 4):542–554
 227. Duffau H (2014) The dangers of magnetic resonance imaging diffusion tensor tractography in brain surgery. *World Neurosurg* 81:56–58
 228. Rheault F, De Benedictis A, Daducci A et al (2020) Tractostorm: The what, why, and how of tractography dissection reproducibility. *Hum Brain Mapp* 41:1859–1874
 229. Berto G, Bullock D, Astolfi P et al (2021) Classifyber, a robust streamline-based linear classifier for white matter bundle segmentation. *Neuroimage* 224:117402
 230. Farquharson S, Tournier JD, Calamante F et al (2013) White matter fiber tractography: why we need to move beyond DTI. *J Neurosurg* 118:1367–1377
 231. Zhan L, Leow AD, Jahanshad N et al (2010) How does angular resolution affect diffusion imaging measures? *Neuroimage* 49:1357–1371
 232. Schult T, Hauser TK, Klose U et al (2019) Fiber visualization for preoperative glioma assessment: tractography versus local connectivity mapping. *PLoS ONE* 14:e0226153
 233. Ashmore J, Pemberton HG, Crum WD et al (2020) Implementation of clinical tractography for pre-surgical planning of space occupying lesions: an investigation of common acquisition and post-processing methods compared to dissection studies. *PLoS ONE* 15:e0231440
 234. Mormina E, Longo M, Arrigo A et al (2015) MRI tractography of corticospinal tract and arcuate fasciculus in high-grade gliomas performed by constrained spherical deconvolution: qualitative and quantitative analysis. *AJNR Am J Neuroradiol* 36:1853–1858
 235. Bucci M, Mandelli ML, Berman JI et al (2013) Quantifying diffusion MRI tractography of the corticospinal tract in brain tumors with deterministic and probabilistic methods. *NeuroImage Clinical* 3:361–368
 236. Caverzasi E, Hervey-Jumper SL, Jordan KM et al (2016) Identifying preoperative language tracts and predicting postoperative functional recovery using HARDI q-ball fiber tractography in patients with gliomas. *J Neurosurg* 125:33–45
 237. Frey D, Strack V, Wiener E et al (2012) A new approach for corticospinal tract reconstruction based on navigated transcranial stimulation and standardized fractional anisotropy values. *Neuroimage* 62:1600–1609
 238. Krieg SM, Buchmann NH, Gempt J et al (2012) Diffusion tensor imaging fiber tracking using navigated brain stimulation—a feasibility study. *Acta Neurochir* 154:555–563
 239. Negwer C, Sollmann N, Ille S et al (2017) Language pathway tracking: comparing nTMS-based DTI fiber tracking with a cubic ROIs-based protocol. *J Neurosurg* 126:1006–1014
 240. Raffa G, Bahrend I, Schneider H et al (2016) A novel technique for region and linguistic specific nTMS-based DTI fiber tracking of language pathways in brain tumor patients. *Front Neurosci* 10:552
 241. Sollmann N, Negwer C, Ille S et al (2016) Feasibility of nTMS-based DTI fiber tracking of language pathways in neurosurgical patients using a fractional anisotropy threshold. *J Neurosci Methods* 267:45–54
 242. Ottenhausen M, Krieg SM, Meyer B et al (2015) Functional preoperative and intraoperative mapping and monitoring: increasing safety and efficacy in glioma surgery. *Neurosurg Focus* 38:E3
 243. Raffa G, Conti A, Scibilia A et al (2018) The impact of diffusion tensor imaging fiber tracking of the corticospinal tract based on navigated transcranial magnetic stimulation on surgery of motor-eloquent brain lesions. *Neurosurgery* 83:768–782
 244. Sollmann N, Giglhuber K, Tussis L et al (2015) nTMS-based DTI fiber tracking for language pathways correlates with language function and aphasia—a case report. *Clin Neurol Neurosurg* 136:25–28
 245. Sanvito F, Caverzasi E, Riva M et al (2020) fMRI-targeted high-angular resolution diffusion MR tractography to identify functional language tracts in healthy controls and glioma patients. *Front Neurosci* 14:225
 246. Campanella M, Ius T, Skrap M et al (2014) Alterations in fiber pathways reveal brain tumor typology: a diffusion tractography study. *PeerJ* 2:e497
 247. Cargnelutti E, Ius T, Skrap M et al (2020) What do we know about pre- and postoperative plasticity in patients with glioma? A review of neuroimaging and intraoperative mapping studies. *NeuroImage Clin* 28:102435
 248. Jenkinson MD, Barone DG, Bryant A et al (2018) Intraoperative imaging technology to maximise extent of resection for glioma. *Cochrane Database System Rev* 1:CD012788
 249. Altieri R, Melcarne A, Di Perna G et al (2018) Intra-operative ultrasound: tips and tricks for making the most in neurosurgery. *Surg Technol Int* 33:353–360
 250. Coburger J, Hagel V, Wirtz CR et al (2015) Surgery for glioblastoma: impact of the combined use of 5-aminolevulinic acid and intraoperative mri on extent of resection and survival. *PLoS ONE* 10:e0131872
 251. Della Pepa GM, Ius T, La Rocca G et al (2020) 5-aminolevulinic acid and contrast-enhanced ultrasound: the combination of the two techniques to optimize the extent of resection in glioblastoma surgery. *Neurosurgery* 86:E529–E540
 252. Faust K, Schneider GH, Vajkoczy P (2019) Utilization of the intraoperative mobile AIRO(R) CT scanner in stereotactic surgery: workflow and effectiveness. *Stereotact Funct Neurosurg* 97:303–312
 253. Mahboob S, McPhillips R, Qiu Z et al (2016) Intraoperative ultrasound-guided resection of gliomas: a meta-analysis and review of the literature. *World Neurosurg* 92:255–263
 254. Orillac C, Stummer W, Orringer DA (2020) Fluorescence guidance and intraoperative adjuvants to maximize extent of resection. *Neurosurgery* 89:727–736

255. Ganslandt O, Behari S, Gralla J et al (2002) Neuronavigation: concept, techniques and applications. *Neurol India* 50:244–255
256. Wang MN, Song ZJ (2011) Classification and analysis of the errors in neuronavigation. *Neurosurgery* 68:1131–1143
257. Shalit MN, Israeli Y, Matz S et al (1979) Intra-operative computerized axial tomography. *Surg Neurol* 11:382–384
258. Yamashita S, Fujisawa M, Kodama K et al (2013) Use of preoperative 3D CT/MR fusion images and intraoperative CT to detect lesions that spread onto the brain surface. *Acta Neurochir Suppl* 118:239–244
259. Hosoda T, Takeuchi H, Hashimoto N et al (2011) Usefulness of intraoperative computed tomography in surgery for low-grade gliomas: a comparative study between two series without and with intraoperative computed tomography. *Neurol Med Chir* 51:490–495
260. Prada F, Del Bene M, Mattei L et al (2015) Preoperative magnetic resonance and intraoperative ultrasound fusion imaging for real-time neuronavigation in brain tumor surgery. *Ultraschall Med* 36:174–186
261. Pavlov V, Meyronet D, Meyer-Bisch V et al (2016) Intraoperative probe-based confocal laser endomicroscopy in surgery and stereotactic biopsy of low-grade and high-grade gliomas: a feasibility study in humans. *Neurosurgery* 79:604–612
262. La Rocca G, Sabatino G, Menna G et al (2020) 5-aminolevulinic acid false positives in cerebral neuro-oncology: not all that is fluorescent is tumor. a case-based update and literature review. *World Neurosurg* 137:187–193
263. Picart T, Armoiry X, Berthiller J et al (2017) Is fluorescence-guided surgery with 5-ala in eloquent areas for malignant gliomas a reasonable and useful technique? *Neurochirurgie* 63:189–196
264. Manini I, Caponnetto F, Dalla E et al (2020) Heterogeneity matters: different regions of glioblastoma are characterized by distinctive tumor-supporting pathways. *Cancers (Basel)* 12:2960
265. Acerbi F, Broggi M, Broggi G et al (2015) What is the best timing for fluorescein injection during surgical removal of high-grade gliomas? *Acta Neurochir* 157:1377–1378
266. Schebesch KM, Proescholdt M, Hohne J et al (2013) Sodium fluorescein-guided resection under the YELLOW 560 nm surgical microscope filter in malignant brain tumor surgery—a feasibility study. *Acta Neurochir* 155:693–699
267. Palmieri G, Cofano F, Salvati LF et al (2021) Fluorescence-guided surgery for high-grade gliomas: state of the art and new perspectives. *Technol Cancer Res Treat* 20:15330338211021604
268. Young JS, Gogos AJ, Aabedi AA et al (2021) Resection of supplementary motor area gliomas: revisiting supplementary motor syndrome and the role of the frontal aslant tract. *J Neurosurg* 23:1–7
269. Berger MS (1995) Functional mapping-guided resection of low-grade gliomas. *Clin Neurosurg* 42:437–452
270. Ius T, Mazzucchi E, Tomasino B et al (2021) Multimodal integrated approaches in low grade glioma surgery. *Sci Rep* 11:9964
271. Sanai N, Mirzadeh Z, Berger MS (2008) Functional outcome after language mapping for glioma resection. *N Engl J Med* 358:18–27
272. Bello L, Riva M, Fava E et al (2014) Tailoring neurophysiological strategies with clinical context enhances resection and safety and expands indications in gliomas involving motor pathways. *Neuro Oncol* 16:1110–1128
273. Sala F (2018) Penfield's stimulation for direct cortical motor mapping: an outdated technique? *Clin Neurophysiol* 129:2635–2637
274. Taniguchi M, Cedzich C, Schramm J (1993) Modification of cortical stimulation for motor evoked potentials under general anesthesia: technical description. *Neurosurgery* 32:219–226
275. Schucht P, Seidel K, Beck J et al (2014) Intraoperative monopolar mapping during 5-ALA-guided resections of glioblastomas adjacent to motor eloquent areas: evaluation of resection rates and neurological outcome. *Neurosurg Focus* 37:E16
276. Raabe A, Beck J, Schucht P et al (2014) Continuous dynamic mapping of the corticospinal tract during surgery of motor eloquent brain tumors: evaluation of a new method. *J Neurosurg* 120:1015–1024
277. Gogos AJ, Young JS, Morshed RA et al (2020) Triple motor mapping: transcranial, bipolar, and monopolar mapping for supratentorial glioma resection adjacent to motor pathways. *J Neurosurg* 134:1728–1737
278. Lombardi G, Barresi V, Castellano A et al (2020) Clinical management of diffuse low-grade gliomas. *Cancers (Basel)* 12:3008
279. Ruda R, Angileri FF, Ius T et al (2020) Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas: an intersociety (SINch/AINO/SIN) document. *J Neurosurg Sci* 64:313–334
280. Kotrotsou A, Elakkad A, Sun J et al (2018) Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. *J Neurooncol* 139:125–133
281. Zelitzki R, Korn A, Arial E et al (2019) Comparison of motor outcome in patients undergoing awake vs general anesthesia surgery for brain tumors located within or adjacent to the motor pathways. *Neurosurgery* 85:E470–E476
282. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. *Polym-brain Tumor Treatment Group Lancet* 345:1008–1012
283. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. *Neuro Oncol* 5:79–88
284. Schueller P, Micke O, Palkovic S et al (2005) 12 years' experience with intraoperative radiotherapy (IORT) of malignant gliomas. *Strahlentherapie und Onkologie* 181:500–506
285. Usyckin S, Calvo F, dos Santos MA et al (2013) Intra-operative electron beam radiotherapy for newly diagnosed and recurrent malignant gliomas: feasibility and long-term outcomes. *Clin Transl Oncol* 15:33–38
286. Sarria GR, Sperk E, Han X et al (2020) Intraoperative radiotherapy for glioblastoma: an international pooled analysis. *Radiotherapy Oncol* 142:162–167
287. Kondziolka D, Lunsford LD (1999) The role of stereotactic biopsy in the management of glioma. *J Neuro-Oncol* 42:205–213
288. Kim JE, Kim DG, Paek SH et al (2003) Stereotactic biopsy for intracranial lesions: reliability and its impact on the planning of treatment. *Acta Neurochir (Wien)* 145:547–554
289. Dammers R, Haitsma IK, Schouten JW et al (2008) Safety and efficacy of frameless and frame-based intracranial biopsy techniques. *Acta Neurochir (Wien)* 150:23–29
290. Lu Y, Yeung C, Radmanesh A et al (2015) Comparative effectiveness of frame-based, frameless, and intraoperative magnetic resonance imaging-guided brain biopsy techniques. *World Neurosurg* 83:261–268
291. Watanabe E, Watanabe T, Manaka S et al (1987) Three-dimensional digitizer (neuronavigator): new equipment for computed tomography-guided stereotaxic surgery. *Surg Neurol* 27:543–547
292. Wu S, Wang J, Gao P et al (2020) A comparison of the efficacy, safety, and duration of frame-based and Remebot robot-assisted frameless stereotactic biopsy. *Br J Neurosurg* 35:1–5
293. Bruno F, Pellerino A, Pronello E et al (2022) Elderly glioblastoma patients: the impact of surgery and adjuvant treatments on survival: a single institution experience. *Brain Sci* 12:632
294. Moriarty TM, Quinones-Hinojosa A, Larson PS et al (2000) Frameless stereotactic neurosurgery using intraoperative

- magnetic resonance imaging: stereotactic brain biopsy. *Neurosurgery* 47:1138–1145
295. Lefranc M, Monet P, Desclos C et al (2012) Perfusion MRI as a neurosurgical tool for improved targeting in stereotactic tumor biopsies. *Stereotact Funct Neurosurg* 90:240–247
 296. McKnight TR, von dem Bussche MH, Vigneron DB et al (2002) Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. *J Neurosurg* 97:794–802
 297. Grech-Sollars M, Vaqas B, Thompson G et al (2017) An MRS- and PET-guided biopsy tool for intraoperative neuronavigational systems. *J Neurosurg* 127:812–818
 298. Pirotte B, Goldman S, Massager N et al (2004) Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. *J Neurosurg* 101:476–483
 299. Chen CC, Hsu PW, Erich Wu TW et al (2009) Stereotactic brain biopsy: Single center retrospective analysis of complications. *Clin Neurol Neurosurg* 111:835–839
 300. Hall WA (1998) The safety and efficacy of stereotactic biopsy for intracranial lesions. *Cancer* 82:1749–1755
 301. Ferreira MP, Ferreira NP, Pereira Filho Ade A et al (2006) Stereotactic computed tomography-guided brain biopsy: diagnostic yield based on a series of 170 patients. *Surg Neurol* 65(S1):27–1–32
 302. McGirt MJ, Woodworth GF, Coon AL et al (2005) Independent predictors of morbidity after image-guided stereotactic brain biopsy: a risk assessment of 270 cases. *J Neurosurg* 102:897–901
 303. Kulkarni AV, Guha A, Lozano A et al (1998) Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy. *J Neurosurg* 89:31–35
 304. Grossman R, Sadetzki S, Spiegelmann R et al (2005) Haemorrhagic complications and the incidence of asymptomatic bleeding associated with stereotactic brain biopsies. *Acta Neurochir (Wien)* 147:627–631
 305. Malone H, Yang J, Hershman DL et al (2015) Complications following stereotactic needle biopsy of intracranial tumors. *World Neurosurg* 84:1084–1089
 306. Steinmetz MP, Barnett GH, Kim BS et al (2001) Metastatic seeding of the stereotactic biopsy tract in glioblastoma multiforme: case report and review of the literature. *J Neurooncol* 55:167–171
 307. Perrin RG, Bernstein M (1998) Iatrogenic seeding of anaplastic astrocytoma following stereotactic biopsy. *J Neurooncol* 36:243–246
 308. Patel N, Sandeman D (1997) A simple trajectory guidance device that assists freehand and interactive image guided biopsy of small deep intracranial targets. *Comput Aid Surg* 2:186–192
 309. Paleologos TS, Dorward NL, Wadley JP et al (2001) Clinical validation of true frameless stereotactic biopsy: analysis of the first 125 consecutive cases. *Neurosurgery* 49:830–835
 310. Chang JH, Kim CY, Choi BS et al (2014) Pseudoprogression and pseudoresponse in the management of high-grade glioma: optimal decision timing according to the response assessment of the neuro-oncology working group. *J Korean Neurosurg Soc* 55:5–11
 311. Parvez K, Parvez A, Zadeh G (2014) The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. *Int J Mol Sci* 15:11832–11846
 312. Sughrue ME, Sheehan T, Bonney PA et al (2015) Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework. *Neurosurg Focus* 38:E11
 313. Sastry RA, Shankar GM, Gerstner ER et al (2018) The impact of surgery on survival after progression of glioblastoma: a retrospective cohort analysis of a contemporary patient population. *J Clin Neurosci* 53:41–47
 314. Kamp MA, Felsberg J, Sadat H et al (2015) 5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy. *Acta Neurochirurgica* 157:207–213
 315. Li X, Jia Z, Yan Y (2022) Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis. *Acta Neurochir* 164:1985–1993
 316. Filippini G, Falcone C, Boiardi A et al (2008) Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. *Neuro Oncol* 10:79–87
 317. De Bonis P, Fiorentino A, Anile C et al (2013) The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. *Clin Neurol Neurosurg* 115:883–886
 318. Hickmann AK, Nadji-Ohl M, Hopf NJ (2015) Feasibility of fluorescence-guided resection of recurrent gliomas using five-aminolevulinic acid: retrospective analysis of surgical and neurological outcome in 58 patients. *J Neurooncol* 122:151–160
 319. Barbagallo GMV, Certo F, Di Gregorio S et al (2021) Recurrent high-grade glioma surgery: a multimodal intraoperative protocol to safely increase extent of tumor resection and analysis of its impact on patient outcome. *Neurosurg Focus* 50:E20
 320. Vargas Lopez AJ, Fernandez Carballal C, Valera Mele M et al (2020) Survival analysis in high-grade glioma: the role of salvage surgery. *Neurologia* 38:21–28
 321. Lombardi G, De Salvo GL, Brandes AA et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet Oncol* 20:110–119
 322. Chang SM, Prados MD, Yung WK et al (2004) Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. *Cancer* 100:1712–1716
 323. Cloughesy TF, Mochizuki AY, Orpilla JR et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. *Nat Med* 25:477–486
 324. Stupp R, Hegi ME, van den Bent MJ et al (2006) Changing paradigms—an update on the multidisciplinary management of malignant glioma. *Oncologist* 11:165–180
 325. Clark AJ, Lamborn KR, Butowski NA et al (2012) Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. *Neurosurgery* 70:361–370
 326. Clark AJ, Butowski NA, Chang SM et al (2011) Impact of bevacizumab chemotherapy on craniotomy wound healing. *J Neurosurg* 114:1609–1616
 327. Pinsky M, Lumenta C (2001) Experiences with reoperation on recurrent glioblastoma multiforme. *Zentralbl Neurochir* 62:43–47
 328. Ortega A, Sarmiento JM, Ly D et al (2016) Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era. *J Clin Neurosci* 24:105–111
 329. Woernle CM, Peus D, Hofer S et al (2015) Efficacy of surgery and further treatment of progressive glioblastoma. *World Neurosurg* 84:301–307
 330. Zanello M, Roux A, Ursu R et al (2017) Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment? *J Neurooncol* 135:285–297
 331. Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. *Clin Cancer Res* 15:6002–6007
 332. Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. *Can Res* 64:6892–6899
 333. Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. *Clin Cancer Res* 19:764–772

334. Schuch P, Murek M, Jilch A et al (2013) Early re-do surgery for glioblastoma is a feasible and safe strategy to achieve complete resection of enhancing tumor. *PLoS ONE* 8:e79846
335. Minniti G, Lombardi G, Paolini S (2019) Glioblastoma in elderly patients: current management and future perspectives. *Cancers* 11:336
336. Buckner JC (2003) Factors influencing survival in high-grade gliomas. *Semin Oncol* 30:10–14
337. Barbagallo GMV, Altieri R, Garozzo M et al (2020) High grade glioma treatment in elderly people: is it different than in younger patients? Analysis of surgical management guided by an intraoperative multimodal approach and its impact on clinical outcome. *Front Oncol* 10:631255
338. Kita D, Ciernik IF, Vaccarella S et al (2009) Age as a predictive factor in glioblastomas: population-based study. *Neuroepidemiology* 33:17–22
339. Paszat L, Laperriere N, Groome P et al (2001) A population-based study of glioblastoma multiforme. *Int J Radiat Oncol Biol Phys* 51:100–107
340. Barnholtz-Sloan JS, Williams VL, Maldonado JL et al (2008) Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. *J Neurosurg* 108:642–648
341. Amsbaugh MJ, Yusuf MB, Gaskins J et al (2017) Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: an analysis of the national cancer data base. *Cancer* 123:3277–3284
342. Ius T, Somma T, Altieri R et al (2020) Is age an additional factor in the treatment of elderly patients with glioblastoma? A new stratification model: an Italian Multicenter Study. *Neurosurg Focus* 49:E13
343. Han Q, Liang H, Cheng P et al (2020) Gross total vs subtotal resection on survival outcomes in elderly patients with high-grade glioma: a systematic review and meta-analysis. *Front Oncol* 10:151
344. Okada M, Miyake K, Tamiya T (2017) Glioblastoma treatment in the elderly. *Neurol Med Chir* 57:667–676
345. Navarria P, Pessina F, Franzese C et al (2021) The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. *Radiotherapy Oncol* 156:49–55
346. Laigle-Donadey F (2021) PL03.1.A surgery for glioblastomas in the elderly: an ANOCEF trial (CSA). *Neuro-Oncology*. <https://doi.org/10.1093/neuonc/noab180.003>
347. Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *Lancet Oncol* 13:707–715
348. Almenawer SA, Badhiwala JH, Alhazzani W et al (2015) Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. *Neuro Oncol* 17:868–881
349. Babu R, Komisarow JM, Agarwal VJ et al (2016) Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. *J Neurosurg* 124:998–1007
350. Chaichana KL, Chaichana KK, Olivi A et al (2011) Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival: clinical article. *J Neurosurg* 114:587–594
351. Noorbakhsh A, Tang JA, Marcus LP et al (2014) Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. *J Neurosurg* 120:31–39
352. Vuorinen V, Hinkka S, Farkkila M et al (2003) Debulking or biopsy of malignant glioma in elderly people—a randomised study. *Acta Neurochir* 145:5–10

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Tamara Ius¹ · Giovanni Sabatino^{2,32} · Pier Paolo Panciani³ · Marco Maria Fontanella³ · Roberta Rudà^{4,5} · Antonella Castellano⁶ · Giuseppe Maria Vincenzo Barbagallo^{7,8} · Francesco Belotti³ · Riccardo Boccaletti⁹ · Giuseppe Catapano¹⁰ · Gabriele Costantino¹¹ · Alessandro Della Puppa¹² · Francesco Di Meco^{13,14,15} · Filippo Gagliardi¹⁶ · Diego Garbossa¹⁷ · Antonino Francesco Germanò¹⁸ · Maurizio Iacoangeli¹⁹ · Pietro Mortini¹⁶ · Alessandro Olivi² · Federico Pessina^{20,21} · Fabrizio Pignotti^{2,32} · Giampaetano Pinna²² · Antonino Raco²³ · Francesco Sala²⁴ · Francesco Signorelli²⁵ · Silvio Sarubbo²⁶ · Miran Skrap¹ · Giannantonio Spena²⁷ · Teresa Somma²⁸ · Carmelo Sturiale²⁹ · Filippo Flavio Angileri¹⁸ · Vincenzo Esposito^{30,31}

Tamara Ius
tamara.ius@gmail.com

Giovanni Sabatino
giovanni.sabatino@materolbia.com

Marco Maria Fontanella
marco.fontanella@unibs.it

Roberta Rudà
rudarob@hotmail.com

Antonella Castellano
castellano.antonella@hsr.it

Giuseppe Maria Vincenzo Barbagallo
giuseppebarbagal@hotmail.com

Francesco Belotti
frbelotti90@gmail.com

Riccardo Boccaletti
riccardoboccaletti@gmail.com

Giuseppe Catapano
giuseppe.catapano@aslnapoli1centro.it

Gabriele Costantino
gabcostantino@gmail.com

Alessandro Della Puppa
alessandro.dellapuppa@unifi.it

Francesco Di Meco
francesco.dimeco@istituto-besta.it

Filippo Gagliardi
gagliardi.filippo@hsr.it

Diego Garbossa
diego.garbossa@unito.it

- Antonino Francesco Germanò
germano@unime.it
- Maurizio Iacoangeli
neurotra@gmail.com
- Pietro Mortini
mortini.pietro@univr.it
- Alessandro Olivi
alessandro.olivi@policlinicogemelli.it
- Federico Pessina
federico.pessina@hunimed.eu
- Fabrizio Pignotti
fabriziopignotti87@gmail.com
- Giampietro Pinna
giampietro.pinna@aovr.veneto.it
- Antonino Raco
antonino.raco@ospedalesantandrea.it
- Francesco Sala
francesco.sala@univr.it
- Francesco Signorelli
fsignorelli@icloud.com
- Silvio Sarubbo
silviosarubbo@gmail.it
- Miran Skrap
skrap@aoud.sanita.fvg.it
- Giannantonio Spena
giannantonios@gmail.com
- Teresa Somma
teresa.somma85@gmail.com
- Carmelo Sturiale
carmelo.sturiale@isnb.it
- Filippo Flavio Angileri
fangileri@unime.it
- Vincenzo Esposito
vincenzo.esposito@uniroma1.it
- 1 Division of Neurosurgery, Head-Neck and NeuroScience Department, University Hospital of Udine, Udine, Italy
 - 2 Institute of Neurosurgery, Fondazione Policlinico Gemelli, Catholic University, Rome, Italy
 - 3 Division of Neurosurgery, Department of Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
 - 4 Department of Neuro-Oncology, University of Turin and City of Health and Science Hospital, 10094 Torino, Italy
 - 5 Neurology Unit, Hospital of Castelfranco Veneto, 31033 Castelfranco Veneto, Italy
 - 6 Department of Neuroradiology, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy
 - 7 Department of Medical and Surgical Sciences and Advanced Technologies (G.F. Ingrassia), Neurological Surgery, Policlinico "G. Rodolico - San Marco" University Hospital, University of Catania, Catania, Italy
 - 8 Interdisciplinary Research Center On Brain Tumors Diagnosis and Treatment, University of Catania, Catania, Italy
 - 9 Neurosurgery Operative Unit, University Hospital of Sassari, Sassari, Italy
 - 10 Division of Neurosurgery, Department of Neurological Sciences, Ospedale del Mare, Naples, Italy
 - 11 Division of Neurosurgery, ARNAS Civico Hospital, Palermo, Italy
 - 12 Neurosurgical Clinical Department of Neuroscience, Psychology, Pharmacology and Child Health, Careggi Hospital, University of Florence, Florence, Italy
 - 13 Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
 - 14 Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
 - 15 Johns Hopkins Medical School, Baltimore, MD, USA
 - 16 Department of Neurosurgery and Gamma Knife Radiosurgery, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy
 - 17 Department of Neuroscience "Rita Levi Montalcini," Neurosurgery Unit, University of Turin, Torino, Italy
 - 18 Division of Neurosurgery, BIOMORF Department, University of Messina, Messina, Italy
 - 19 Department of Neurosurgery, Università Politecnica Delle Marche, Azienda Ospedali Riuniti, Ancona, Italy
 - 20 Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Milan, Italy
 - 21 Neurosurgery Department, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy
 - 22 Unit of Neurosurgery, Department of Neurosciences, Hospital Trust of Verona, 37134 Verona, Italy
 - 23 Division of Neurosurgery, Department of NESMOS, AOU Sant'Andrea, Sapienza University, Rome, Italy
 - 24 Department of Neurosciences, Biomedicines and Movement Sciences, Institute of Neurosurgery, University of Verona, 37134 Verona, Italy
 - 25 Department of Basic Medical Sciences, Neuroscience and Sense Organs, Neurosurgery Unit, University "Aldo Moro", 70124 Bari, Italy
 - 26 Department of Neurosurgery, Santa Chiara Hospital, Azienda Provinciale Per I Servizi Sanitari (APSS), Trento, Italy
 - 27 Neurosurgery Unit, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
 - 28 Division of Neurosurgery, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Università Degli Studi Di Napoli Federico II, Naples, Italy
 - 29 Neurosurgery Operative Unit, Bellaria Hospital, Bologna, Italy
 - 30 Department of Neurosurgery "Giampaolo Cantore"-IRCCS Neuromed, Pozzilli, Italy
 - 31 Department of Human, Neurosciences-"Sapienza" University of Rome, Rome, Italy
 - 32 Unit of Neurosurgery, Mater Olbia Hospital, Olbia, Italy